Tumors or cancer of the LUNG.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
A malignant epithelial tumor with a glandular organization.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A cell line derived from cultured tumor cells.
A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Neuropeptide and gut hormone that helps regulate GASTRIC ACID secretion and motor function. Once released from nerves in the antrum of the STOMACH, the neuropeptide stimulates release of GASTRIN from the GASTRIN-SECRETING CELLS.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
Pathological processes involving any part of the LUNG.
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
A hydro-lyase that catalyzes the dehydration of 2-phosphoglycerate to form PHOSPHOENOLPYRUVATE. Several different isoforms of this enzyme exist, each with its own tissue specificity.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A tetradecapeptide originally obtained from the skins of toads Bombina bombina and B. variegata. It is also an endogenous neurotransmitter in many animals including mammals. Bombesin affects vascular and other smooth muscle, gastric secretion, and renal circulation and function.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Tumors or cancer of the LIVER.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Cell surface proteins that bind bombesin or closely related peptides with high affinity and trigger intracellular changes influencing the behavior of cells. Gastrin- releasing peptide (GRP); GRP 18-27 (neuromedin C), and neuromedin B are endogenous ligands of bombesin receptors in mammals.
DNA present in neoplastic tissue.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.
Antibodies produced by a single clone of cells.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
Damage to any compartment of the lung caused by physical, chemical, or biological agents which characteristically elicit inflammatory reaction. These inflammatory reactions can either be acute and dominated by NEUTROPHILS, or chronic and dominated by LYMPHOCYTES and MACROPHAGES.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Transplantation between animals of different species.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
The excision of lung tissue including partial or total lung lobectomy.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
An organoplatinum compound that possesses antineoplastic activity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
The transference of either one or both of the lungs from one human or animal to another.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Tumors or cancer of the BRONCHI.
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
Established cell cultures that have the potential to propagate indefinitely.
Elements of limited time intervals, contributing to particular results or situations.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
One of the AROMATIC-L-AMINO-ACID DECARBOXYLASES, this enzyme is responsible for the conversion of DOPA to DOPAMINE. It is of clinical importance in the treatment of Parkinson's disease.
An autoimmune disease characterized by weakness and fatigability of proximal muscles, particularly of the pelvic girdle, lower extremities, trunk, and shoulder girdle. There is relative sparing of extraocular and bulbar muscles. CARCINOMA, SMALL CELL of the lung is a frequently associated condition, although other malignancies and autoimmune diseases may be associated. Muscular weakness results from impaired impulse transmission at the NEUROMUSCULAR JUNCTION. Presynaptic calcium channel dysfunction leads to a reduced amount of acetylcholine being released in response to stimulation of the nerve. (From Adams et al., Principles of Neurology, 6th ed, pp 1471)
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Tumors or cancer of the human BREAST.
RNA present in neoplastic tissue.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
A group of acidic proteins that are major components of SECRETORY GRANULES in the endocrine and neuroendocrine cells. They play important roles in the aggregation, packaging, sorting, and processing of secretory protein prior to secretion. They are cleaved to release biologically active peptides. There are various types of granins, usually classified by their sources.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
The exposure of the head to roentgen rays or other forms of radioactivity for therapeutic or preventive purposes.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)
A type I keratin found associated with KERATIN-7 in ductal epithelia and gastrointestinal epithelia.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
The relationship between the dose of an administered drug and the response of the organism to the drug.
A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
Tumors or cancer of the THYROID GLAND.
A sarcoma characterized by the presence of small cells, cells measuring 9-14 micrometers with a faint or indistinct rim of cytoplasm and an oval-to-elongated nucleus with relatively dense chromatin. (From Segen, Dictionary of Modern Medicine, 1992)
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.
Tumors or cancer of the ESOPHAGUS.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
Tumors or cancer of the NASOPHARYNX.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
A type of chromogranin which was first isolated from CHROMAFFIN CELLS of the ADRENAL MEDULLA but is also found in other tissues and in many species including human, bovine, rat, mouse, and others. It is an acidic protein with 431 to 445 amino acid residues. It contains fragments that inhibit vasoconstriction or release of hormones and neurotransmitter, while other fragments exert antimicrobial actions.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Agents that inhibit PROTEIN KINASES.
Cerebellar degeneration associated with a remote neoplasm. Clinical manifestations include progressive limb and GAIT ATAXIA; DYSARTHRIA; and NYSTAGMUS, PATHOLOGIC. The histologic type of the associated neoplasm is usually carcinoma or lymphoma. Pathologically the cerebellar cortex and subcortical nuclei demonstrate diffuse degenerative changes. Anti-Purkinje cell antibodies (anti-Yo) are found in the serum of approximately 50% of affected individuals. (Adams et al., Principles of Neurology, 6th ed, p686)
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the URINARY BLADDER.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
A condition of HYPONATREMIA and renal salt loss attributed to overexpansion of BODY FLUIDS resulting from sustained release of ANTIDIURETIC HORMONES which stimulates renal resorption of water. It is characterized by normal KIDNEY function, high urine OSMOLALITY, low serum osmolality, and neurological dysfunction. Etiologies include ADH-producing neoplasms, injuries or diseases involving the HYPOTHALAMUS, the PITUITARY GLAND, and the LUNG. This syndrome can also be drug-induced.
A system of NEURONS that has the specialized function to produce and secrete HORMONES, and that constitutes, in whole or in part, an ENDOCRINE SYSTEM or organ.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Inhaling and exhaling the smoke of burning TOBACCO.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
A MARVEL domain-containing protein found in the presynaptic vesicles of NEURONS and NEUROENDOCRINE CELLS. It is commonly used as an immunocytochemical marker for neuroendocrine differentiation.
Specialized NEURONS that produce hormones, such as NEUROPEPTIDES or BIOGENIC AMINES. They generally are in the NERVOUS SYSTEM, such as HYPOTHALAMUS, but can be found in other organs or systems. These neurons contain dense neurosecretory granules and PROPROTEIN CONVERTASES allowing the rapidly release of NEUROHORMONES into the blood circulation upon stimulation.
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
The action of a drug in promoting or enhancing the effectiveness of another drug.
Endoscopic examination, therapy or surgery of the bronchi.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
Family of retrovirus-associated DNA sequences (myc) originally isolated from an avian myelocytomatosis virus. The proto-oncogene myc (c-myc) codes for a nuclear protein which is involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Truncation of the first exon, which appears to regulate c-myc expression, is crucial for tumorigenicity. The human c-myc gene is located at 8q24 on the long arm of chromosome 8.
A carcinoma thought to be derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
Biochemical identification of mutational changes in a nucleotide sequence.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
Tumors or cancer of the SKIN.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Treatment that combines chemotherapy with radiotherapy.
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Degenerative or inflammatory conditions affecting the central or peripheral nervous system that develop in association with a systemic neoplasm without direct invasion by tumor. They may be associated with circulating antibodies that react with the affected neural tissue. (Intern Med 1996 Dec;35(12):925-9)
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
A diffuse or multifocal peripheral neuropathy related to the remote effects of a neoplasm, most often carcinoma or lymphoma. Pathologically, there are inflammatory changes in peripheral nerves. The most common clinical presentation is a symmetric distal mixed sensorimotor polyneuropathy. (Adams et al., Principles of Neurology, 6th ed, p1334)
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
Tumors or cancer of the COLON.
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
Cells with the capacity to take up and decarboxylate the amine precursors DIHYDROXYPHENYLALANINE or 5-HYDROXYTRYPTOPHAN. This is a property of endocrine cells of neural and non-neural origin. APUDOMA is a general term collectively applied to tumors associated with APUD cells.
The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI.
A mixture of six synthetic oligopeptides, each containing MELPHALAN. It is used as a broad-spectrum antineoplastic due to its alkylating and antimetabolic actions but, is toxic to bone marrow, gastrointestinal system and vasculature.
Tumors or cancer of the STOMACH.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES.
Tumors or cancer of the MOUTH.
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)
Actual loss of portion of a chromosome.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
Measurement of the amount of air that the lungs may contain at various points in the respiratory cycle.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety.
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
A paraneoplastic syndrome marked by degeneration of neurons in the LIMBIC SYSTEM. Clinical features include HALLUCINATIONS, loss of EPISODIC MEMORY; ANOSMIA; AGEUSIA; TEMPORAL LOBE EPILEPSY; DEMENTIA; and affective disturbance (depression). Circulating anti-neuronal antibodies (e.g., anti-Hu; anti-Yo; anti-Ri; and anti-Ma2) and small cell lung carcinomas or testicular carcinoma are frequently associated with this syndrome.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)

Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. (1/7523)

The association of p53 abnormalities with the prognosis of patients with non-small cell lung carcinoma (NSCLC) has been extensively investigated to date, however, this association is still controversial. Therefore, we investigated the prognostic significance of p53 mutations through exons 2 to 11 and p53 protein expression in 103 cases of stage I NSCLC. p53 mutations were detected in 49 of 103 (48%) tumors. Two separate mutations were detected in four tumors giving a total of 53 unique mutations in 49 tumors. Ten (19%) of mutations occurred outside exons 5-8. Positive immunohistochemical staining of p53 protein was detected in 41 of 103 (40%) tumors. The concordance rate between mutations and protein overexpression was only 69%. p53 mutations, but not expression, were significantly associated with a shortened survival of patients (P<0.001). Furthermore, we investigated the correlation between the types of p53 mutations and prognosis. p53 missense mutations rather than null mutations were associated with poor prognosis (P < 0.001 in missense mutations and P=0.243 in null mutations). These results indicated that p53 mutations, in particular missense mutations, rather than p53 expression could be a useful molecular marker for the prognosis of patients with surgically resected stage I NSCLC.  (+info)

Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. (2/7523)

OBJECTIVE: To determine the sensitivity, specificity, and accuracy of positron emission tomography with 2-fluorine-18-fluorodeoxyglucose (PET-FDG) in the preoperative staging (N and M staging) of patients with lung cancer. The authors wanted to compare the efficacy of PET scanning with currently used computed tomography (CT) scanning. MATERIALS AND METHODS: Results of whole-body PET-FDG imaging and CT scans were compared with histologic findings for the presence or absence of lymph node disease or metastatic sites. Sampling of mediastinal lymph nodes was performed using mediastinoscopy or thoracotomy. RESULTS: PET-FDG imaging was significantly more sensitive, specific, and accurate for detecting N disease than CT. PET changed N staging in 35% and M staging in 11% of patients. CT scans helped in accurate anatomic localization of 6/57 PET lymph node abnormalities. CONCLUSION: PET-FDG is a reliable method for preoperative staging of patients with lung cancer and would help to optimize management of these patients. Accurate lymph node staging of lung cancer may be ideally performed by simultaneous review of PET and CT scans.  (+info)

Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. (3/7523)

Tissue factor (TF) is an initiator of the extrinsic cascade of blood coagulation. Although recent studies have revealed a relationship between metastatic properties and TF expression in some neoplastic cells, the significance of TF in lung cancer, especially in non-small-cell lung cancer (NSCLC), is still unclear. In this study, TF was detected in NSCLC cell lines by functional study, Western blot analysis and immunocytochemical staining. TF levels in eight NSCLC cell lines were also quantitated by enzyme-linked immunosorbent assay (ELISA), and TF expression was evaluated in 55 specimens of surgically resected NSCLCs. NSCLC cell lines derived from metastatic lesions produced high levels of TF (48.3+/-23.5 ng 10(-6) cells, mean +/- s.e.m.), whereas those derived from primary lesions produced low levels of TF (0.2+/-0.1 ng 10(-6) cells). Immunohistochemical studies disclosed significantly stronger staining for TF in cells from NSCLC patients with metastasis than in those without metastasis. Among the 28 patients with metastasis, ten were strongly positive, 16 were moderately positive and two were negative for TF. In contrast, among the 27 patients without metastasis, only two were strongly positive, 18 were moderately positive and seven were negative for TF. Therefore, malignant cells from patients with lung cancer produce various levels of TF, and TF may play an important role in the metastatic process.  (+info)

Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast. (4/7523)

Lung cancer is now the number one cause of cancer death for both men and women. An age-adjusted analysis over the past 25 years shows that in women specifically, lung cancer incidence is on the rise. It is estimated that 10-20 genetic events including the alteration of oncogenes and tumor suppressor genes will have occurred by the time a lung tumor becomes clinically evident. In an effort to identify regions containing novel cancer genes, chromosome 18p11, a band not previously implicated in disease, was examined for loss of heterozygosity (LOH). In this study, 50 matched normal and NSCLC tumor samples were examined using six 18p11 and one 18q12.3 PCR-based polymorphic markers. In addition, LOH was examined in 29 glioblastoma pairs and 14 paired breast carcinomas. This analysis has revealed potentially two regions of LOH in 18p11 in up to 38% of the tumor samples examined. The regions of LOH identified included a 2 cm area between markers D18S59 and D18S476, and a more proximal, 25 cm region of intermediate frequency between D18S452 and D18S453. These results provide evidence for the presence of one or more potential tumor suppressor genes on the short arm of chromosome 18 which may be involved in NSCLC, brain tumors and possibly breast carcinomas as well.  (+info)

Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. (5/7523)

BACKGROUND: Conventional cytologic analysis of sputum is an insensitive test for the diagnosis of non-small-cell lung cancer (NSCLC). We have recently demonstrated that polymerase chain reaction (PCR)-based molecular methods are more sensitive than cytologic analysis in diagnosing bladder cancer. In this study, we examined whether molecular assays could identify cancer cells in bronchoalveolar lavage (BAL) fluid. METHODS: Tumor-specific oncogene mutations, CpG-island methylation status, and microsatellite alterations in the DNA of cells in BAL fluid from 50 consecutive patients with resectable (stages I through IIIa) NSCLC were assessed by use of four PCR-based techniques. RESULTS: Of 50 tumors, 28 contained a p53 mutation, and the identical mutation was detected with a plaque hybridization assay in the BAL fluid of 39% (11 of 28) of the corresponding patients. Eight of 19 adenocarcinomas contained a K-ras mutation, and the identical mutation was detected with a mutation ligation assay in the BAL fluid of 50% (four of eight) of the corresponding patients. The p16 gene was methylated in 19 of 50 tumors, and methylated p16 alleles were detected in the BAL fluid of 63% (12 of 19) of the corresponding patients. Microsatellite instability in at least one marker was detected with a panel of 15 markers frequently altered in NSCLC in 23 of 50 tumors; the identical alteration was detected in the BAL fluid of 14% (three of 22) of the corresponding patients. When all four techniques were used, mutations or microsatellite instability was detected in the paired BAL fluid of 23 (53%) of the 43 patients with tumors carrying a genetic alteration. CONCLUSION: Although still limited by sensitivity, molecular diagnostic strategies can detect the presence of neoplastic cells in the proximal airway of patients with surgically resectable NSCLC.  (+info)

Trimodality therapy in stage III non-small cell lung cancer: prediction of recurrence by assessment of p185neu. (6/7523)

In a trimodality treatment approach for stage III non-small cell lung cancer the prognostic impact of pretherapeutic p185neu assessment was evaluated. Fifty-four patients were admitted to chemotherapy followed by twice-daily radiation with concomittant low-dose chemotherapy and subsequent surgery. Immunohistochemical assessment of p185neu expression was performed in paraffin-embedded mediastinal lymph node metastases, by mediastinoscopy biopsy prior to therapy. Paraffin-embedded biopsies of mediastinal lymph node metastases were available in 33 cases. Seven out of eight patients with positive p185neu staining developed distant metastases, in contrast to seven out of 25 negative cases. Expression of p185neu in mediastinal lymph node metastases was a significant predictor for progression-free survival (p=0.047) and resulted mainly from significant differences in metastases-free survival (p185neu-positive versus p185neu-negative: median, 11 versus 19 months; 2- and 3-yr rates, 13% and 0% versus 40% and 32%; p=0.04). On the basis of these preliminary results it was concluded that further evaluation of p185neu expression in trials on neoadjuvant and adjuvant therapy is warranted. When the prognostic impact of p185neu in such trials with larger patient numbers is confirmed, this may contribute to the identification of stratification variables for future treatment approaches of non-small cell lung cancer.  (+info)

Combined modality therapy of lung cancer. (7/7523)

Combined modality therapy for lung cancer was first demonstrated to be successful in limited-stage small cell lung cancer. Concurrent administration of chemotherapy with chest and elective brain irradiation appears to produce the best results, with cisplatin/etoposide as the core chemotherapy. Using such programs, 2-year survival in the 40% range and 5-year survivals in excess of 20% may be expected, based on the results of multiple studies. Attempts to improve on these results through the use of altered schemes of chest irradiation or the delivery of high-dose consolidation chemotherapy are ongoing but to date have not been shown to affect survival significantly. We remain at a plateau in the effectiveness of combined modality therapy for small cell lung cancer, with little evidence that it impacts survival at all in extensive-stage disease. The incorporation of new agents in combination chemotherapy regimens, more "specific" immunotherapy directed at tumor-associated antigens, and the potential adjunctive use of broad-spectrum neuropeptide antagonists offer promise for the future. In non-small cell lung cancer, the sequential use of platinum-based chemotherapy and chest irradiation appears superior in survival to standard, daily fractionated radiation therapy used alone, with long-term survival increased from 5-10% to 15-20%. Concurrent administration of chemotherapy with cisplatin/etoposide and chest irradiation produces 2-year survival in the range of 30%, about twice that would be expected for radiation therapy alone, but has not been compared to it in the setting of a randomized trial. Low-dose cisplatin on a daily basis has been combined as a "sensitizer" with chest irradiation, producing initial results that appeared encouraging. However, these have not been reproduced in subsequent, randomized trials. Another approach to combined modalities has been to give chemotherapy or chemotherapy/radiation therapy as induction, followed by surgical resection, with or without subsequent additional treatment. Most patients (80-85%) can be resected, with encouraging survival at 2 and 3 years in the Southwest Oncology Group experience (37 and 26%, respectively). However, toxicity is greater, and such an approach is associated with an overall mortality risk in the range of 10%. A current intergroup study attempts to define the role of surgery in this setting. The major recent development that is likely to influence the future of combined modality therapy for this disease is the advent of multiple new chemotherapeutic agents, such as the taxanes, gemcitabine, vinorelbine, and the topoisomerase-I inhibitors, which have activity in stage IV disease. The immediate challenge is how to combine these agents with platinum analogues, radiation, and surgery. Aiding this process may be the use of molecular biological "markers" that may predict the chance of success or failure with a given systemic agent. The next decade is likely to see substantial improvements in the outcome of treatment for patients with stages I-III non-small cell lung cancer, based on the systemic exploration of combined modalities.  (+info)

The expression of beta-catenin in non-small-cell lung cancer: a clinicopathological study. (8/7523)

AIMS: To investigate the expression of beta-catenin in non-small-cell lung cancer (NSCLC) and its clinical significance. METHODS: 101 patients were surgically treated for NSCLC by lobectomy or pneumectomy with systematic lymph node dissection. Follow up was available in all patients, ranging from 24 to 110 months. Immunostaining of tissue sections from primary tumours and (when present) their lymph node metastases was performed and evaluated using a monoclonal antibody against beta-catenin. Correlations were investigated between beta-catenin immunostaining in primary tumours and E-cadherin immunostaining (data available from a previous study), lymph node stage, and survival. RESULTS: There were significant correlations between scores for beta-catenin immunostaining and E-cadherin immunostaining in primary tumours (p = 0.007), and between the beta-catenin immunostaining score in primary tumours and in their lymph node metastases (p = 0.006). An inverse correlation was found between the beta-catenin immunostaining score in primary tumours and lymph node stage N0, N1, or N2 (p = 0.03). According to the Kaplan-Meier survival estimate, the level of beta-catenin expression in primary tumours was a statistically significant prognostic factor (p = 0.01). CONCLUSIONS: Reduced beta-catenin expression in surgically treated NSCLC is clearly associated with lymph node metastasis and an infavourable prognosis. The existence of a functional relation between E-cadherin and beta-catenin is supported by the results of this clinicopathological study.  (+info)

TY - JOUR. T1 - Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer. T2 - The eastern cooperative oncology group results. AU - Chang, A. Y.. AU - Kim, K.. AU - Glick, J.. AU - Anderson, T.. AU - Karp, D.. AU - Johnson, D.. PY - 1993/3/3. Y1 - 1993/3/3. N2 - Background: Patients with metastatic (stage IV) non-small-cell lung cancer usually have a poor prognosis and disease refractory to chemotherapy. Three new agents-taxol, merbarone, and piroxantrone-have shown promising antitumor treatment in vitro and in animals. Taxol is an antimicrotubular agent that interferes with mitosis during cell division. Merbarone, a conjugate of thiobarbituric acid and aniline, is a topoisomerase II inhibitor, which thus inhibits DNA synthesis and tumor growth. Piroxantrone, an anthracenedione derivative, is a DNA intercalating agent that has shown potent antitumor activity in animal studies. Purpose: Our randomized phase II study was designed to evaluate the efficacy and ...
1. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V. et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. The New England journal of medicine. 2006;355:983-91 2. Hubner RA, Riley RD, Billingham LJ, Popat S. Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS One. 2011;6:e25164 3. Allingham-Hawkins D, Lea A, Levine S. ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer. PLoS Curr. 2010;2:RRN1202 4. Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T. et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci. 2007;98:1336-43 5. Malottki K, Popat S, Deeks JJ, Riley RD, Nicholson AG, Billingham L. Problems of variable biomarker evaluation in stratified medicine research-A case ...
Ionic channel activity is involved in fundamental cellular behaviour and participates in cancerous features such as proliferation, migration and invasion which in turn contribute to the metastatic process. In this study, we investigated the expression and role of voltage-gated sodium channels in non-small-cell lung cancer cell lines. Functional voltage-gated sodium channels expression was investigated in normal and non-small-cell lung cancer cell lines. The measurement, in patch-clamp conditions, of tetrodotoxin-inhibitable sodium currents indicated that the strongly metastatic cancerous cell lines H23, H460 and Calu-1 possess functional sodium channels while normal and weakly metastatic cell lines do not. While all the cell lines expressed mRNA for numerous sodium channel isoforms, only H23, H460 and Calu-1 cells had a 250 kDa protein corresponding to the functional channel. The other cell lines also had another protein of 230 kDa which is not addressed to the membrane and might act as a dominant
TY - JOUR. T1 - Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. AU - Perng, Reury Perng. AU - Chen, Yuh Min. AU - Ming-Liu, Jacqueline. AU - Tsai, Chun Ming. AU - Lin, Wei Chun. AU - Yang, Kuang Yao. AU - Whang-Peng, Jacqueline. N1 - Copyright: Copyright 2020 Elsevier B.V., All rights reserved.. PY - 1997/1/1. Y1 - 1997/1/1. N2 - Purpose: A phase II randomized study was conducted to evaluate the efficacy and toxicity of gemcitabine (GEM) versus the combination of cisplatin and etoposide (EP) in Chinese patients with inoperable (stage III or IV) non-small-cell lung cancer (NSCLC). Patients and Methods: From March 1995 to February 1996, 53 patients were enrolled onto the study: 27 onto the GEM arm and 26 onto the EP arm. In the GEM arm, gemcitabine 1,250 mg/m2 was given as a 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle. In the EP arm, cisplatin 80 mg/m2 was given on ...
Management of local recurrences and regional failure in early stage non-small cell lung cancer after stereotactic body radiation therapy
The purpose of this trial is to examine the safety and immunogenicity of a therapeutic vaccine regimen with recombinant DNA and adenovirus expressing L523S protein in patients with early stage non-small cell lung cancer. The vaccine regimen will consist of two fixed doses of recombinant DNA (pVAX/L523S) followed by two doses of recombinant adenovirus (Ad/L523S). The trial will evaluate the dose escalation of Ad/L523S through three cohorts of patients ...
Lung cancer is the leading cause of cancer-related mortality. Therapies against non-small cell lung cancer (NSCLC) are particularly needed, as this type of cancer is relatively insensitive to chemotherapy and radiation therapy. We recently identified GGTI compounds that are designed to block geranylgeranylation and membrane association of signaling proteins including the Rho family G-proteins. One of the GGTIs is P61A6 which inhibits proliferation of human cancer cells, causes cell cycle effects with G1 accumulation and exhibits tumor-suppressing effects with human pancreatic cancer xenografts. In this paper, we investigated effects of P61A6 on non-small cell lung cancer (NSCLC) cells in vitro and in vivo. Three non-small cell lung cancer cell lines were used to test the ability of P61A6 to inhibit cell proliferation. Further characterization involved analyses of geranylgeranylation, membrane association and activation of RhoA, and anchorage-dependent and -independent growth, as well as cell cycle
OBJECTIVES:. I. To assess the safety and efficacy of a combination of vinorelbine and paclitaxel administered weekly to elderly patients with advanced non-small cell lung cancer.. II. To assess the response rate of a combination of vinorelbine and paclitaxel administered weekly to elderly patients with advanced non-small cell lung cancer.. III. To assess the quality of life of elderly patients with advanced non-small cell lung cancer during administration of weekly paclitaxel and vinorelbine.. OUTLINE:. Patients receive vinorelbine tartrate intravenously (IV) over 6-10 minutes and paclitaxel IV over 1 hour once weekly for 6 weeks. Treatment repeats every 8 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 5 years. ...
TY - JOUR. T1 - Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer. T2 - Preliminary results comparing sequential phase II trials. AU - DeVore, R. F.. AU - Jagasia, M.. AU - Johnson, D. H.. PY - 1997/10/22. Y1 - 1997/10/22. N2 - Our group previously described the activity of carboplatin plus paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) (given as a 24-hour infusion) in 51 patients with advanced non-small cell lung cancer. To facilitate outpatient administration, the regimen was modified to infuse paclitaxel over 1 hour. Between February 1995 and August 1996, 63 patients with advanced non-small cell lung cancer were accrued by the Vanderbilt Cancer Center and its affiliate network. The first four patients received paclitaxel 175 mg/ml2; all subsequent patients received paclitaxel 200 mg/m2. The carboplatin dose was determined using the Calvert formula, with a target area under the concentration-time curve of 6. ...
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib works in treating patients with stage IIIB or stage IV non-small cell lung cancer that has not responded to chemotherapy.
TY - JOUR. T1 - Use of MicroRNA expression levels to predict outcomes in resected stage i non-small cell lung cancer. AU - Duncavage, Eric. AU - Goodgame, Boone. AU - Sezhiyan, Ananth. AU - Govindan, Ramaswamy. AU - Pfeifer, John. PY - 2010/11. Y1 - 2010/11. N2 - Background: Despite undergoing curative resection, nearly a third of patients with stage I non-small cell lung cancer (NSCLC) die of recurrent disease. There are no reliable clinical or molecular predictors of relapse in patients with resected stage I NSCLC. Identifying patients at risk for relapse after surgical resection is one of the important challenges today. MicroRNAs (miRNAs) regulate hundreds of genes central to maintaining a cancer phenotype. Methods: In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with ...
TY - JOUR. T1 - Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. AU - Gjerstorff, Morten F. AU - Pøhl, Mette. AU - Olsen, Karen E. AU - Ditzel, Henrik J. PY - 2013. Y1 - 2013. N2 - The unique expression pattern and immunogenic properties of cancer/testis antigens make them ideal targets for immunotherapy of cancer. The MAGE-A3 cancer/testis antigen is frequently expressed in non-small cell lung cancer (NSCLC) and vaccination with MAGE-A3 in patients with MAGE-A3-positive NSCLC has shown promising results. However, little is known about the expression of other cancer/testis antigens in NSCLC. In the present study the expression of cancer/testis antigens GAGE, NY-ESO-1 and SP17 was investigated in patients with completely resected, early stage, primary NSCLC.. AB - The unique expression pattern and immunogenic properties of cancer/testis antigens make them ideal targets for immunotherapy of cancer. The MAGE-A3 cancer/testis antigen ...
Excerpt:. Patients with advanced non-small-cell lung cancer survive four months longer with fewer side effects on an immunotherapy drug called atezolizumab compared to chemotherapy, according to a phase 3 clinical trial published in The Lancet.. The trial enrolled 1225 advanced non-small-cell lung cancer patients who have no more treatment options, but this study used an early analysis of the first 850 patients from the trial. Half of the group were given atezolizumab and the other half were given docetaxel chemotherapy, which is the standard treatment for advanced non-small-cell lung cancer.. Patients given atezolizumab - a drug that blocks the programmed death ligand 1 (PD-L1) protein - survived for an average of 13.8 months, compared with 9.6 months for those on chemotherapy.. Go to full article.. ...
This phase II trial is studying how well erlotinib works in treating patients with advanced primary non-small cell lung cancer. Erlotinib may stop the g
PURPOSE OF REVIEW: The first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, are effective as first-line treatment of advanced nonsmall cell lung cancer (NSCLC) harboring activating EGFR mutations (deletions in exon 19 and exon 21 L858R mutation). EGFR T790 M resistance mutation (EGFR T790 M) ultimately emerged in most of these patients. The second and third-generation EGFR-TKIs were designed to have more potent inhibition of EGFR and to overcome EGFR T790 M. This review describes the recent developments of these novel EGFR-TKIs.. RECENT FINDINGS: The second-generation EGFR-TKIs, afatinib and dacomitinib, irreversibly bind to the tyrosine kinase of EGFR and other ErbB-family members. Afatinib has been approved as first-line treatment of advanced NSCLC harboring activating EGFR mutations. Dacomitinib is under development. Third-generation EGFR-TKIs, AZD9291, CO-1686, and HM61713, inhibit both EGFR activating and resistance mutations, ...
This phase II trial is studying how well saracatinib works in treating patients with recurrent, stage IIIB or stage IV non-small cell lung cancer previo
SOTIO presented new statistically and clinically significant results from its Phase I/II clinical trial evaluating DCVAC/LuCa, an active cellular immunotherapy product, in patients with stage IV non-small cell lung cancer. The final analysis of the data confirmed the promising clinical efficacy of DCVAC/LuCa.
TY - JOUR. T1 - Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. AU - Zhu, Chang Qi. AU - Ding, Keyue. AU - Strumpf, Dan. AU - Weir, Barbara A.. AU - Meyerson, Matthew. AU - Pennell, Nathan. AU - Thomas, Roman K.. AU - Naoki, Katsuhiko. AU - Ladd-Acosta, Christine. AU - Liu, Ni. AU - Pintilie, Melania. AU - Der, Sandy. AU - Seymour, Lesley. AU - Jurisica, Igor. AU - Shepherd, Frances A.. AU - Tsao, Ming Sound. PY - 2010/10/10. Y1 - 2010/10/10. N2 - Purpose: The JBR.10 trial demonstrated benefit from adjuvant cisplatin/vinorelbine (ACT) in early-stage non-small-cell lung cancer (NSCLC). We hypothesized that expression profiling may identify stage-independent subgroups who might benefit from ACT. Patients and Methods: Gene expression profiling was conducted on mRNA from 133 frozen JBR.10 tumor samples (62 observation [OBS], 71 ACT). The minimum gene set that was selected for the greatest separation of good and poor prognosis patient ...
TY - JOUR. T1 - Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer. AU - Baldini, E.. AU - Tibaldi, C.. AU - Chella, A.. AU - Angeletti, C. A.. AU - Silvano, G.. AU - Andrei, A.. AU - Algeri, R.. AU - Conte, P. F.. PY - 1996/9. Y1 - 1996/9. N2 - Purpose: to evaluate the combination of vinorelbine, ifosfamide and cisplatin (VIP) in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: Seventy-six untreated patients with stages IIIB-IV NSCLC; the chemotherapy regimen consisted of vinorelbine (25 mg/sqm on days 1 and 8), ifosfamide (3 g/sqm on day 1 with uroprotective mesna), and cisplatin (80 mg/sqm on day 1). The cycles were administered on an outpatient basis every 3 weeks. Results: Leukopenia was the most frequent toxicity: grades 3-4 neutropenia was observed in 26% of the cycles and 19 episodes of febrile neutropenia were reported in 289 evaluable courses. Filgrastim 5 μg/kg was administered in 27% of the ...
TY - JOUR. T1 - Patients preferences for treatment outcomes for advanced non-small cell lung cancer. T2 - A conjoint analysis. AU - Bridges, John F.P.. AU - Mohamed, Ateesha F.. AU - Finnern, Henrik W.. AU - Woehl, Anette. AU - Hauber, A. Brett. PY - 2012/7. Y1 - 2012/7. N2 - Background: Treatment decisions for advanced non-small cell lung cancer (NSCLC) are complex and require trade-offs between the benefits and risks experienced by patients. We evaluated the benefits that patients judged sufficient to compensate for the risks associated with therapy for NSCLC. Methods: Participants with a self-reported diagnosis of NSCLC (n= 100) were sampled from an online panel in the United Kingdom. Eligible and consenting participants then completed a self-administered online survey about their disease and their treatment preferences were assessed. This involved respondents choosing among systematically paired profiles that spanned eight attributes: progression-free survival [PFS], symptom severity, rash, ...
Effect of pulmonary wedge resection on Ia stage non-small cell lung cancer of elderly patients, its effect on serum anti-survivin antibody, Hsp90Ã Â and CEA levels, Run-hua Ti
TY - JOUR. T1 - Inhibitory effect of dihydroaustrasulfone alcohol on the migration of human non-small cell lung carcinoma A549 cells and the antitumor effect on a Lewis lung carcinoma-bearing tumor model in C57BL/6J mice. AU - Chen, Shuo Chueh. AU - Chien, Yi Chung. AU - Pan, Chun Hsu. AU - Sheu, Jyh Horng. AU - Chen, Chih Yi. AU - Wu, Chieh Hsi. PY - 2014/1. Y1 - 2014/1. N2 - There are many major causes of cancer death, including metastasis of cancer. Dihydroaustrasulfone alcohol, which is isolated from marine coral, has shown antioxidant activity, but has not been reported to have an anti-cancer effect. We first discovered that dihydroaustrasulfone alcohol provided a concentration-dependent inhibitory effect on the migration and motility of human non-small cell lung carcinoma (NSCLC) A549 cells by trans-well and wound healing assays. The results of a zymography assay and Western blot showed that dihydroaustrasulfone alcohol suppressed the activities and protein expression of matrix ...
This study will examine the effectiveness of a drug called Tarceva (erlotinib) giving prior to surgery in lung cancer patients. To be eligible for the study patients must have stage III Non-Small Cell Lung Cancer with EGFR mutation. Eligible patients will take Tarceva® (erlotinib) at a dose of 150 mg daily for approximately two months. After 2 months of erlotinib treatment, patients will have a PET/CT scan to determine whether they are responding to the treatment (i.e. whether or not the tumor shrunk or remains stable) or not. After the treatment patients will then be evaluated by a surgeon for surgical removal of the remaining tumor. Treatment after the surgery will be determined by the treating physician and it will be influenced by the response to treatment with Tarceva (erlotinib). A total of 55 patients with will take part in this multi-institution study.
TY - JOUR. T1 - Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations. T2 - The okayama lung cancer study group trial 1001. AU - Ichihara, Eiki. AU - Hotta, Katsuyuki. AU - Nogami, Naoyuki. AU - Kuyama, Shoichi. AU - Kishino, Daizo. AU - Fujii, Masanori. AU - Kozuki, Toshiyuki. AU - Tabata, Masahiro. AU - Harada, Daijiro. AU - Chikamori, Kenichi. AU - Aoe, Keisuke. AU - Ueoka, Hiroshi. AU - Hosokawa, Shinobu. AU - Bessho, Akihiro. AU - Hisamoto-Sato, Akiko. AU - Kubo, Toshio. AU - Oze, Isao. AU - Takigawa, Nagio. AU - Tanimoto, Mitsune. AU - Kiura, Katsuyuki. PY - 2015/3/30. Y1 - 2015/3/30. N2 - Purpose: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains unknown. We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as ...
Sox2 and Oct4 are transcription factors with the characteristics of regulating self-renewal and differentiation of embryonic stem cell. The aim of this study was to detect the expression of Sox2 and Oct4 and analyze their clinical significance in human non-small-cell lung cancer (NSCLC). Expression of Sox2 and Oct4 were assayed in cancer tissues and their corresponding paracancerous tissues from 44 patients with NSCLC and 21 patients with benign tumors using immunohistochemistry, Western blot, reverse transcription polymerase chain reaction (RT-PCR). The correlation between the expression of Sox2 and Oct4 and tumor type, grade and prognosis and the utility of the two genes in discriminating between benign and malignant tumors were analyzed as well. The results showed that Sox2 and Oct4 positive staining was only seen in the nuclei of cancer cells but not in either the precancerous tissues or benign tumor tissues by immunohistochemistry (p | 0.01). Furthermore, in the lung cancer tissue, the positive
Tumour angiogenesis is an important factor for tumour growth and metastasis. Although some recent reports suggest that microvessel counts in non-small cell lung cancer are related to a poor disease outcome, the results were not conclusive and were not compared with other molecular prognostic markers. In the present study, the vascular grade was assessed in 107 (T1,2-N0,1) operable non-small cell lung carcinomas, using the JC70 monoclonal antibody to CD31. Three vascular grades were defined with appraisal by eye and by Chalkley counting: high (Chalkley score 7-12), medium (5-6), and low (2-4). There was a significant correlation between eye appraisal and Chalkley counting (P | 0.0001). Vascular grade was not related to histology, grade, proliferation index (Ki67), or EGFR or p53 expression. Tumours from younger patients had a higher grade of angiogenesis (P = 0.05). Apart from the vascular grade, none of the other factors examined was statistically related to lymph node metastasis (P | 0.0001). A
TY - JOUR. T1 - Chemoradiotherapy for poor-risk stage III non-small cell lung cancer.. AU - Lau, Derick H. AU - Ryu, J. K.. AU - Gandara, David R. PY - 1997/8. Y1 - 1997/8. N2 - Cisplatin-based chemoradiotherapy is becoming a standard treatment for patients with stage III non-small cell lung cancer (NSCLC). However, a significant proportion of patients with lung cancer also present with co-morbid conditions that indicate a poor prognosis and poor tolerance of treatment. We have completed a phase I/II study to evaluate the tolerability and efficacy of carboplatin-based chemoradiotherapy for patients with poor-risk stage III NSCLC. Twenty-four patients with stage IIIA/B NSCLC and concurrent medical conditions rendering them ineligible for cisplatin-based chemoradiotherapy protocols were treated with thoracic irradiation, 1.8 to 2 Gy daily to the primary tumor and regional lymph nodes, for a total dose of 61 Gy. Concurrently, patients received carboplatin 200 mg/m2/d intravenously on days 1, 3, 29, ...
TY - JOUR. T1 - Imaging characteristics of local recurrences after stereotactic body radiation therapy for stage I non-small cell lung cancer. T2 - Evaluation of mass-like fibrosis. AU - Hayashi, Shinya. AU - Tanaka, Hidekazu. AU - Hoshi, Hiroaki. PY - 2015/3/1. Y1 - 2015/3/1. N2 - Background: This study aimed to evaluate stereotactic body radiation therapy (SBRT) in patients with stage I non-small cell lung cancer (NSCLC) in terms of radiation-induced changes and computed tomography (CT) features of local recurrence by 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET). Methods: From January 2006 to December 2012, 81 patients with NSCLC received SBRT. Follow-up consisted of non-contrast enhanced CT scans performed before and every four months after SBRT. In addition, 18F-FDG-PET/CT was conducted before SBRT for each patient, and one year later for each case suspected of recurrence. The CT findings were classified into two categories: mass-like fibrosis and others. The mass-like ...
A look at the following clinical trial: Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours
A look at the following clinical trial: Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours
125I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy:a comparison with best supportive care Jingjing Song* Xiaoxi Fan* Zhongwei Zhao* Minjiang Chen* Weiqian Chen, Fazong Wu, Dengke Zhang, Li Chen, Jianfei Tu, Jiansong Ji Department of Interventional Radiology, Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui, Zhejiang, Peoples Republic of China *These authors have contributed equally to this work Objectives: The objective of this study was to assess the efficacy of computed tomography (CT)-guided 125I brachytherapy alone in improving the survival and quality of life of patients with unresectable locally advanced non-small-cell lung cancer (NSCLC) after one cycle of first-line chemotherapy.Patients and methods: Sixteen patients with locally advanced NSCLC were treated with CT-guided 125I brachytherapy after one cycle of first-line chemotherapy (group A). Sixteen
TY - JOUR. T1 - Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer. T2 - A retrospective study with pharmacogenetic evaluation. AU - Metro, Giulio. AU - Chiari, R.. AU - Mare, M.. AU - Giannarelli, D.. AU - Tofanetti, F. R.. AU - Minotti, V.. AU - Ferraldeschi, M.. AU - Giuffrida, D.. AU - Marcomigni, L.. AU - Bennati, C.. AU - Fischer, M. J.. AU - Meacci, M.. AU - Bellavita, R.. AU - Pistola, L.. AU - Ludovini, V.. AU - Crinò, L.. PY - 2011/12. Y1 - 2011/12. N2 - Purpose: In the present study, the combination of carboplatin (CBDCA) plus pemetrexed (PMX) for the treatment of patients with platinum-pretreated, pemetrexed-naïve, advanced non-small cell lung cancer (NSCLC) was investigated. Also, single nucleotide polymorphisms (SNPs) at the XRCC3, XPD, ERCC1, GARFT, DHFR, and TS genes were investigated. Methods: Eighty patients treated with CBDCA/PMX at two Italian institutions were evaluable. Of these, 73 patients had blood samples collected for ...
The purpose of this study was to compare patterns of failure between lobar resection (lobectomy or pneumonectomy) and stereotactic body radiation therapy (SBRT) for patients with clinical stage I non-small-cell lung cancer (NSCLC). From January
Imfinzi demonstrated unprecedented survival in unresectable, Stage III non-small cell lung cancer with an estimated 50% of patients surviving four years
Could the Neutrophil to Lymphocyte Ratio be a Poor Prognostic Factor for Non Small Cell Lung Cancers? Lung cancer;neutrophil to lymphocyte ratio;prognostic factors;C reactive protein; Background: Although many prognostic factors have been identified for lung cancers, new ones are needed to determine the course of the disease. Recently, a high neutrophil to lymphocyte ratio (NLR) prior to surgery or treatment has been shown to be an indicator of prognosis for cancer. The aim of this study was to investigate the value of NLR as a prognostic factor and the correlation between NLR and other probable clinical prognostic factors in non small cell lung cancer patients prior to treatment. Materials and Methods: Data of patients who were diagnosed with non-small cell lung cancer in our institution were retrospectively reviewed. Demographic and clinicopathologic characteristics were recorded. NLR was calculated before the application of any treatment. Results: A total of 299 patients, 270 (90%) males and 29 (10
Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor. Clinical trials have reported its effectiveness in the treatment of brain metastases from non-small cell lung cancer by overcoming the blood-brain barrier. Gefitinib is generally regarded as a relatively safe agent, and several reports have described its efficacy in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and a poor performance status. We herein described two patients with brain metastasis from non-small cell lung cancer who achieved the total regression of metastasis with the administration of gefitinib. A 70-year-old Japanese woman was referred to our hospital with a severe cough. Brain magnetic resonance imaging revealed a metastatic lesion in the left temporal lobe. The tumor was positive for an epidermal growth factor receptor L858R mutation in exon 21 using the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method. She was treated with 250 mg
Doctor answers on Symptoms, Diagnosis, Treatment, and More: Dr. Wright on life chances with non small cell lung cancer: Stage 1 nsclc; surgical resection, appr70%5yrsurv stage2nsclc;surgery apprx. 30-35% 5 yr survival. for topic: Life Chances With Non Small Cell Lung Cancer
[130 Pages Report] Check for Discount on United States Non Small Cell Lung Cancer Therapeutics Industry 2016 Market Research Report report by QYResearch Group. The United States Non Small Cell Lung Cancer Therapeutics Industry...
Several factors, including regional UVB levels, vitamin D intake, skin pigmentation, sunlight exposure behaviors, and adiposity may influence in vivo vitamin D levels (21). Seasonal variation in 25(OH)D concentrations have been observed for residents in Boston (10-13), with inadequate vitamin D intake and winter season being independent predictors of hypovitaminosis D (13). We investigated the effects of season and vitamin D intake on NSCLC survival and found that both higher UVB exposure (patients who had surgery in summer) and higher vitamin D intake (diet and supplement) improved lung cancer survival. Patients who had surgery in summer with high vitamin D intake had a 3-fold better RFS and a 4-fold better OS than those with surgery in winter and low vitamin D intake, with all of the other patient groups falling between the two groups (Table 4; Fig. 2). In Cox proportional hazards models, we adjusted for the most important predictors of NSCLC prognosis, including age, gender, smoking status, ...
Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) have recently been described in patients with non-small-cell lung cancer (NSCLC) who achieve radiographic regressions to the EGFR inhibitor gefitinib. One of these mutations, L858R (Leu→Arg), is also found in NSCLC cell line H3255, which is very sensitive to gefitinib treatment. We characterized nine NSCLC cell lines (three isolated from patients with bronchioloalveolar carcinoma and six isolated from patients with adenocarcinoma) for their in vitro sensitivity to gefitinib. Of these, only H3255 (EGFRL858R) and H1666 (EGFRWT) are sensitive to gefitinib with IC50 values of 40 nmol/L and 2 μmol/L, respectively. We examined the effects of gefitinib on H3255 and cell lines containing wild-type EGFR that are either sensitive (H1666) or resistant (A549 and H441) to gefitinib exposure in vitro. Gefitinib treatment (1 μmol/L) leads to significant apoptosis accompanied by increased poly(ADP-ribose) ...
For patients with Stage III non-small cell lung cancer, prophylactic (preventive) radiation therapy to the brain reduces the risk of brain metastases but carries a risk of memory problems and doesnt appear to improve overall survival. These results were published in the Journal of Clinical Oncology.. Lung cancer remains the leading cause of cancer death in the United States. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers.. One of the sites to which NSCLC can spread (metastasize) is the brain. Brain metastases can have a profound effect on survival and quality of life.. Prophylactic cranial irradiation (PCI) refers to the administration of radiation to the brain before brain metastases become apparent. The goal of PCI is the prevention of brain metastases. Previous studies have suggested that PCI can reduce the occurrence of brain metastases, but PCI has not become a part of routine NSCLC care because of concern about side effects and lack of evidence that ...
Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults
Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults
An increasing number of chromosomal aberrations is being identified in solid tumors providing novel biomarkers for various types of cancer and new insights into the mechanisms of carcinogenesis. We applied next generation sequencing technique to analyze the transcriptome of the non-small cell lung carcinoma (NSCLC) cell line H2228 and discovered a fusion transcript composed of multiple exons of ALK (anaplastic lymphoma receptor tyrosine kinase) and PTPN3 (protein tyrosine phosphatase, nonreceptor Type 3). Detailed analysis of the genomic structure revealed that a portion of genomic region encompassing Exons 10 and 11 of ALK has been translocated into the intronic region between Exons 2 and 3 of PTPN3. The key net result appears to be the null mutation of one allele of PTPN3, a gene with tumor suppressor activity. Consistently, ectopic expression of PTPN3 in NSCLC cell lines led to inhibition of colony formation. Our study confirms the utility of next generation sequencing as a tool for the ...
The clinical significance of carbon-ion radiotherapy (CIRT) for octogenarians with locally advanced non-small-cell lung cancer (LA-NSCLC) remains unclear.
Disorders of cell adhesion are critical steps in cancer progression in which varieties of markers including cadherins are involved in.Btbd7 was found to inhibit E-cadherin expression in MDCK cells and play important roles during branching morphogenesis of embryonic salivary glands and lungs. However its function in malignant tumors is largely unknown. The aim of this study is to investigate the clinicopathological significance and possible function of Btbd7 in non-small cell lung cancer. Immunohistochemistry and Western blotting were used to investigate Btbd7 expression in non-small cell lung cancer and lung tissues. The clinicopathological association and the overall survival was analyzed. In vitro experiments were performed using siRNA to investigate the function of Btbd7 in lung cancer cells. Btbd7 expression was elevated in non-small cell lung cancer tissues compared to normal lung tissues. Increased Btbd7 expression was significantly associated with lymph node metastasis, reduced E-cadherin
Non-small cell lung cancer is the most common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer.
Non-small cell lung cancer is the most common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer.
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
The purpose of this study is to find out if adding the study drug, nivolumab, after surgery and chemotherapy will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the bodys immune system to attack any cancer cells that may remain after surgery.
Among patients with metastatic non-small-cell lung cancer, early palliative care led to significant improvements in both quality of life and mood. As compared with patients receiving standard care, patients receiving early palliative care had less aggressive care at the end of life but longer surviv …
Introduction: A phase-II study was planned to test the effect of external beam radiotherapy in combination with endobronchial brachytherapy on the local control and survival of stage-III non-small cell lung cancer patients. Materials and methods: Thirty patients with stage-III non-small cell lung cancer have been treated with 60 Gy external beam radiotherapy and 3 x 5 Gy HDR endobronchial brachytherapy to control tumor and to prolong survival. Results: Therapy regimen was found to be very effective for the palliation of major symptoms, palliation rates were 42.8% for cough, 95.2% for hemoptysis, 88.2% for chest pain and 80.0% for dyspnea. There was a 76.7% tumor response (53.3% complete, 23.3% partial) verified by chest CT scans and bronchoscopy. However, median locoregional disease free survival was 9 +/- 4 months (95% Cl: 1-17) and it was only 9.6% at 5 years. Major side effects were radiation bronchitis (70.0%), esophagitis (6.6%) in the acute period and bronchial fibrosis (25%), esophagial ...
Objective: Lung cancer is the leading cause of cancer-related mortality worldwide. Disease stage still remains the best prognostic factor for patients with localized non-small cell lung cancer. The TNM staging system, however, does not address the heterogeneity of this disease. Sub-classification and identification of distinct prognostic sub-groups within each stage may allow the optimization of clinical trial design and potentially improve outcome. This is a retrospective pilot study, in which we attempt to identify genomic biomarkers predictive of recurrence in stage I lung cancer by analysing copy number (CN) data obtained by next-generation sequencing. Materials and Methods: Ninety eight patients with stage I NSCLC, who underwent elective radical surgery were identified from a tissue bank of 323 tumour samples. Their demographic and surgical data, including their recurrence status were collected and an extensive database compiled. The cases were split into two cohorts depending on their ...
TY - JOUR. T1 - Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy. T2 - A review of the national cancer data base. AU - Robinson, Cliff G.. AU - Patel, Aalok P.. AU - Bradley, Jeffrey D.. AU - DeWees, Todd. AU - Waqar, Saiama N.. AU - Morgensztern, Daniel. AU - Baggstrom, Maria Q.. AU - Govindan, Ramaswamy. AU - Bell, Jennifer M.. AU - Guthrie, Tracey J.. AU - Colditz, Graham A.. AU - Crabtree, Traves D.. AU - Kreisel, Daniel. AU - Krupnick, Alexander S.. AU - Patterson, G. Alexander. AU - Meyers, Bryan F.. AU - Puri, Varun. N1 - Publisher Copyright: © 2015 by American Society of Clinical Oncology. Copyright: Copyright 2015 Elsevier B.V., All rights reserved.. PY - 2015/3/10. Y1 - 2015/3/10. N2 - Purpose To investigate the impact of modern postoperative radiotherapy (PORT) on overall survival (OS) for patients with N2 non-small-cell lung cancer (NSCLC) treated nationally with surgery and adjuvant chemotherapy. Patients and Methods ...
Lung cancer remains the major cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) account for at least 80% of all lung tumors and about 30% of them present with unresectable locally advanced disease at diagnosis (stage IIIA-IIIB) [1]. Until the mid 1980s standard treatment of patients with inoperable locally advanced NSCLC consisted of radiotherapy (RT) alone with a median survival time of 10 months[1]. From data about lung cancer population diagnosed in the second half of 1990s, overall survival at one and two years was estimated of 36% and 12% respectively[2].. Rates at 2 and 5 years of 15% and 5% respectively [3]. In attempts to improve the survival in these patients, chemotherapy was added to external beam irradiation. Several trials have been positive in favour of combined therapy [4-6]. More recently, other clinical trials have shown that, in selected patients (good performance status, age ≤ 75 years and minimal weight loss) concomitant platinum-based ...
Chemotherapy is one of the most important options for NSCLC and this therapeutic process is also a heavy burden for patients. Agents derived from various plants have been considered as potential alternative or auxiliary cure for cancer patients because research has shown that these therapeutic agents had no side effects, or at least the side effects were much more moderate compared with that of clinical first line chemotherapeutics. The anticancer effects of phloretin have been confirmed in various cancers (15-17), while its anti-cancer effects and underlying mechanisms on NSCLC is still uncertain. The aim of the present study was to evaluate the anticancer effects of phloretin on NSCLC cell lines and the results revealed that phloretin could exert anticancer effects on NSCLC cell lines and it also enhanced the anticancer effects of cisplatin.. In order to elucidate the effects of phloretin on cell vitality, MTT assay and flow cytometry were, respectively, carried out. MTT results showed that ...
Inactivation of the p16 and ESR1 tumor suppressor genes by promoter lesion methylation has been reported in many tumor types, including lung cancer. We examined the blood of 95 non-small cell lung cancer patients (66 cases of adenocarcinoma, 23 of squamous cell carcinoma and 6 of large cell carcinoma) and 30 controls consisting of normal subjects and benign disease patients to determine the methylation ratios of p16 and ESR1 using real-time PCR. For both genes, there was a statistically significant difference in the methylation ratio between non-small cell lung cancer patients and controls (p16; ...
Background: Tumor-infiltrating immune cells analyzed by immunohistochemistry are reported as alternative prognostic factors to supplement TNM staging in operable non-small cell lung cancer (NSCLC), but little is done by flow cytometry. Method: We established a protocol to analyze immune cells in tumor, distant lung (far from tumor) and peripheral blood mononuclear cells (PBMCs) by 8 color flow cytometry. 30 NSCLC patients with adenocarcinoma, squamous cell carcinoma and more uncommon histotypes were included and statistical analyses of cell subsets were performed. Results: We have identified the following tumor-infiltrating immune cells: CD45+ leukocytes, granulocytes, CD19+ B cells, CD4+ and CD8+ T cells with naïve/memory phenotype, CD56+CD16+ and CD56+CD16- NK cells, CD14+ macrophages, CD123+ plasmacytoid dendritic cells (pDCs), CD1c+ myeloid dendritic cells (mDCs) and CD141+ mDCs. There was an increase in leukocyte numbers in tumor compared with distant lung in adenocarcinoma. When expressed ...
TY - JOUR. T1 - Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer. AU - Kawata, Toshio. AU - Higashimori, Mitsuo. AU - Itoh, Yohji. AU - Tomkinson, Helen. AU - Johnson, Martin G.. AU - Tang, Weifeng. AU - Nyberg, Fredrik. AU - Jiang, Haiyi. AU - Tanigawara, Yusuke. PY - 2019/5/1. Y1 - 2019/5/1. N2 - Purpose: A prospective, multicenter, large-scale cohort with a nested case-control study (NCT00252759) was conducted to identify and quantify risk factors for interstitial lung disease (ILD) in Japanese patients with non-small-cell lung cancer who received gefitinib. This study reports the association between gefitinib exposure and the occurrence of ILD. Methods: A total of 1891 gefitinib plasma concentrations from 336 patients were measured after first dose, at steady state, and at time of ILD occurrence. Influences of demographic and pathophysiological factors on pharmacokinetics were investigated by non-linear mixed-effect modeling. ...
TY - JOUR. T1 - A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer. AU - Argiris, A.. AU - Liptay, M.. AU - LaCombe, M.. AU - Marymont, M.. AU - Kies, M. S.. AU - Sundaresan, S.. AU - Masters, G.. N1 - Copyright: Copyright 2008 Elsevier B.V., All rights reserved.. PY - 2004/8. Y1 - 2004/8. N2 - Purpose: We designed a phase I/II trial in order to evaluate the efficacy and tolerability of induction carboplatin and gemcitabine and the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of subsequent chemoradiotherapy with weekly vinorelbine and paclitaxel in patients with stage III non-small cell lung cancer (NSCLC). Patients and methods: Patients had pathologically confirmed N2-N3 stage NSCLC, adequate end-organ function, and ECOG performance status 0-2. Carboplatin was administered at an AUC of 5 on day 1 and gemcitabine 1000 mg/m2 on ...
TY - JOUR. T1 - Circulating plasma DNA in non-small cell lung cancer patients is not influenced by inflammatory pulmonary conditions. AU - van der Drift, M.A.. AU - Hol, B.E.A.. AU - Klaassen, C.D.. AU - Prinsen, C.. AU - van Aarssen, Y.A.W.G.. AU - Dekhuijzen, P.N.R.. AU - van der Stappen, J.W.J.. AU - Thunnissen, F.B.J.M.. PY - 2009. Y1 - 2009. M3 - Article. VL - 4. SP - S903-S903. JO - Journal of Thoracic Oncology. JF - Journal of Thoracic Oncology. SN - 1556-0864. IS - 9. ER - ...
non-seminomatous germ cell tumors PEI cisplatin, etoposide, ifosfamide small-cell lung carcinoma ... "A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) ... B cell non-Hodgkin lymphoma FCM-R or R-FCM or R-FMC or FMC-R fludarabine, cyclophosphamide, mitoxantrone plus rituximab B cell ... B cell non-Hodgkin lymphoma R-ICE or ICE-R or RICE rituximab + ICE; that is, rituximab, ifosfamide, carboplatin, etoposide high ...
2006). „K-ras mutations in non-small-cell lung carcinoma: a review". Clinical Lung Cancer. Cancer Information Group. 8 (1): 30- ... Većina tipova plućnih kancera su plućni karcinomi malih-ćelija (engl. small-cell lung carcinoma, SCLC). Najčešći simptomi su ... 2006). „Small cell lung cancer". Annals of Oncology. 17 (Suppl. 2): 5-10. PMID 16608983. doi:10.1093/annonc/mdj910.. ... Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms". Clinical Lung Cancer. 12 (5): 261- ...
Small cell lung carcinoma (SCLC) (FDA Oct 2007). As of 2016, experiments were under way for Neuroblastoma, Brainstem glioma, ... Topotecan is often given in combination with Paclitaxel as first line treatment for extensive-stage small-cell lung cancer. ... "FDA Rubber-Stamps APP Pharma's Generic Topotecan for Small Cell Lung and Cervical Cancers". 30 Nov 2010. DNA Topoisomerases and ... In addition, topotecan is experimentally treating Non-small cell lung cancer, Colorectal Cancer, Breast cancer, Non-Hodgkin ...
"K-ras mutations in non-small-cell lung carcinoma: a review". Clinical Lung Cancer (Cancer Information Group) 8 (1): 30-38. PMID ... Detailed guide: Lung cancer - small cell American Cancer Society ((. en. )). *Detailed guide: Lung cancer - non-small cell ... Većina tipova plućnih kancera su plućni karcinomi malih-ćelija (engl. small-cell lung carcinoma, SCLC). Najčešći simptomi su ... "Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms". Clinical Lung Cancer 12 (5): 261-271 ...
Syrian hamsters are a model for researching Non-small-cell lung carcinoma, which is one of the types of human lung cancer. In ... "Current role of surgery in small cell lung carcinoma". Journal of Cardiothoracic Surgery. 4 (1): 30. doi:10.1186/1749-8090-4-30 ... Oral squamous-cell carcinoma is a common cancer in humans and difficult to treat. Scientists studying this disease broadly ... The scientist can take cell samples from the mouth of the hamster to measure the development of the cancer. This process has ...
Smoking can be linked to all subtypes of lung cancer. Small Cell Lung Carcinoma (SCLC) is the most closely associated with ... Kalemkerian, G. P., Akerley, W., Bogner, P., Borghaei, H., Chow, L. Q., Downey, R. J., … Hughes, M. (2013). Small Cell Lung ... Maneckjee R, Minna JD (October 1994). "Opioids induce while nicotine suppresses apoptosis in human lung cancer cells". Cell ... If the mutation inhibits programmed cell death, the cell can survive to become a cancer, a cell that does not function like a ...
"Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma". Br. J. Cancer. 96 ... cell adhesion. • positive regulation of osteoblast differentiation. • chondrocyte proliferation. • positive regulation of cell ... Cell Genet. 61 (4): 274-5. doi:10.1159/000133421. PMID 1486804.. *. Abedinia M, Layfield R, Jones SM, Nixon PF, Mattick JS ( ... extracellular domain in pichia pastoris and functional analysis in synovial fibroblasts and NIT3T3 cells". Mol. Cell. Biochem. ...
It was counterproductive in non-squamous non-small-cell lung carcinoma. International Nonproprietary Names for Pharmaceutical ... name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma ... Chustecka Z (2015-11-22). "Necitumumab (Portrazza) Approved for Lung Cancer in US". Medscape.com. Retrieved 2019-09-28. " ...
Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer". Archived from the original on 2013-01-19. ... It has also been studied for the treatment of bladder carcinoma[5] and gastric cancer.[6] ... "Pharmion's Amrubicin Shows Encouraging Results Compared To Standard Of Care In Second Line Treatment Of Small Cell Lung Cancer" ... Amrubicin (INN; previously known as SM-5887) is an anthracycline used in the treatment of lung cancer.[1] It is marketed in ...
... small-cell lung cancer, ovarian cancer). It has been granted Orphan drug status for Merkel cell carcinoma. It has reported ... "ImmunoGen Announces Encouraging New Clinical Data With The Company's IMGN901 Compound In The Treatment Of Small-Cell Lung ... encouraging Phase II results for small-cell lung cancer. Dimond PF (9 March 2010). "Antibody-Drug Conjugates Stage a Comeback ... It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a ...
Increased expression of mir-126 inhibits cell proliferation of non-small cell lung carcinoma cells in vitro and prevents tomour ... "MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines". Biochem Biophys Res Commun. 373 (4): 607-12. doi: ... Sun Y, Bai Y, Zhang F, Wang Y, Guo Y, Guo L (2010). "miR-126 inhibits non-small cell lung cancer cells proliferation by ... This includes controlled cell death and responses to wounds. During apoptosis cell death, cells release apoptotic bodies ...
... -containing drugs Gefitinib for treatment of non-small-cell lung carcinoma. Lapatinib for treatment of advanced- ... "Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to ... Lapatinib eliminates the growth of breast cancer stem cells that cause tumor growth. The binding of lapatinib to the ATP- ... the cancer stem cell. Archived from the original on 2008-11-26. Nelson MH, Dolder CR (February 2006). "Lapatinib: a novel dual ...
... small cell lung carcinoma. Maksym Pashayev, 20, Ukrainian footballer, car accident. Amalia Solórzano, 97, Mexican First Lady ( ... Kenny Cox, 68, American jazz musician, lung cancer. Sir Bernard Crick, 79, British political theorist, cancer. Dock Ellis, 63, ... David Lieber, 83, Polish-born American biblical scholar, lung ailment. John W. Powell, 89, Chinese-born American journalist ... Ron Carey, 72, American labor leader (Teamsters), lung cancer. Robert Chandler, 80, American CBS executive, heart failure. Elie ...
Possible applications include non-small-cell lung carcinoma, hepatocellular carcinoma, and oesophageal cancer. In 2017, it was ... Tivantinib (ARQ197; by Arqule, Inc.) is an experimental small molecule anti-cancer drug. It is a bisindolylmaleimide that binds ... "ArQule Announces Commencement of Phase 3 Clinical Trial with Tivantinib in Hepatocellular Carcinoma by Partner Kyowa Hakko ... announced that a phase III clinical trial for advanced hepatocellular carcinoma had failed to meet the primary endpoint. " ...
Trueman was diagnosed with small cell carcinoma of the lung in May 2006. He died of the disease on 1 July 2006 at Airedale ... This award was discontinued in 2004, two years before Trueman was diagnosed with lung cancer, because its organisers feared it ...
July). „K-ras mutations in non-small-cell lung carcinoma: a review". Clinical Lung Cancer 8 (1), 30-38. o, Kiadó: Cancer ... A nem-kissejtes (Non-small cell lung carcinoma) elváltozásokat egy csoportba sorolják, mivel kezelésük és kimenetelük hasonló. ... Non-Small Cell Lung Cancer Treatment -Patient Version (PDQ®). NCI , 2015. május 12. [2016. február 29-i dátummal az eredetiből ... a b c Lung Carcinoma: Tumors of the Lungs. Merck Manual Professional Edition, Online edition. [2007. augusztus 16-i dátummal az ...
... , sold under the brand name Gilotrif among others, is a medication used to treat non-small cell lung carcinoma (NSCLC). ... It has received regulatory approval for use as a treatment for non-small cell lung cancer,[6][4][7][8] although there is ... May 2012). "Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of ... "Role of afatinib in the treatment of advanced lung squamous cell carcinoma". Clinical Pharmacology. 9: 147-157. doi:10.2147/ ...
In lung carcinoma, fibronectin expression is increased especially in non-small cell lung carcinoma. The adhesion of lung ... ISBN 978-0-387-97050-9. Han S, Khuri FR, Roman J (January 2006). "Fibronectin stimulates non-small cell lung carcinoma cell ... The RGD sequence (Arg-Gly-Asp) is located in III10 and is the site of cell attachment via α5β1 and αVβ3 integrins on the cell ... "Fibronectin 1 is a potential biomarker for radioresistance in head and neck squamous cell carcinoma". Cancer Biology & Therapy ...
... and non-small-cell lung carcinoma, which can be addicted to the gene EGFR. Oncogene addiction can be treated by using enzyme ... As a result, cancer cells rely on continuous signaling from these oncogenes for their survival. The term was coined in 2002 by ... Tulpule, Asmin; Bivona, Trever G. (2020). "Acquired Resistance in Lung Cancer". Annual Review of Cancer Biology. 4: 279-297. ... Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells". Biomarkers in Cancer. 7s2 (Suppl 2): 25-32. doi:10.4137/BIC.S29326 ...
In adults, most cases are associated with breast carcinoma or small-cell lung carcinoma. It is one of the few paraneoplastic ( ... and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes". Neurology. 62 (9): 1526-32. doi: ... possibly by expanding the memory B cell population. Studies have generally asserted that 70-80% of children with OMS will have ...
Shtivelman E (Jun 1997). "A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma". Oncogene ... Cell. Biol. 20 (2): 583-93. doi:10.1128/MCB.20.2.583-593.2000. PMC 85138. PMID 10611237. Xiao H, Palhan V, Yang Y, Roeder RG ( ... Cell. Biol. 24 (16): 7091-101. doi:10.1128/MCB.24.16.7091-7101.2004. PMC 479715. PMID 15282309. Suzuki Y, Yamashita R, Shirota ... NicAmhlaoibh R, Shtivelman E (2001). "Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro". ...
Middle mediastinum: lymphadenopathy, metastatic disease such as from small cell carcinoma from the lung. Posterior mediastinum ... It is surrounded by the chest wall in front, the lungs to the sides and the spine at the back. It extends from the sternum in ... It contains all the organs of the thorax except the lungs. It is continuous with the loose connective tissue of the neck. The ... Chandra S, Laor YG (April 1975). "Lung scan and wide mediastinum". J. Nucl. Med. 16 (4): 324-5. PMID 1113190. von Kodolitsch Y ...
Lemmo, W; Tan, G (2016). "Prolonged Survival After Dichloroacetate Treatment of Non-Small-Cell Lung Carcinoma-Related ... cell death) of the malignant cells. In vitro work with DCA on neuroblastomas (which have fewer recognised mitochondrial ... These effects were not observed in non-tumor cells. Neuropathy has been a problem in some clinical trials with DCA causing them ... It can kill normal cells as well. A randomized controlled trial in children with congenital lactic acidosis found that while ...
He died of small cell lung carcinoma in Yerevan prison on October 8, 1940. "Sahak Torosyan - Wikipedia, the free encyclopedia ...
... not have non-superficial squamous-cell carcinoma or a mixture of both small-cell carcinoma and non-small-cell lung carcinoma or ... The PARAMOUNT trial is a clinical trial studying non-small-cell lung carcinoma (NSCLC). The trial was sponsored by Eli Lilly ... For patients with advanced non-small cell lung carcinoma (NSCLC), maintenance therapy is sometimes used when the initial ... participants must in the trial must have stage IIIB or IV nonsquamous non-small-cell lung carcinoma and have at least one ...
1994). "A hippocampal protein associated with paraneoplastic neurologic syndrome and small cell lung carcinoma". Biochem. ... Cell. Biol. 20 (13): 4765-72. doi:10.1128/MCB.20.13.4765-4772.2000. PMC 85909. PMID 10848602. Sakai K, Kitagawa Y, Hirose G ( ...
... of non-small-cell lung cancers; promoter hypermethylation of MLH1 occurs in 48% of squamous cell carcinomas; and promoter ... of non-small-cell lung cancers; promoter hypermetylation of ATM occurs in 47% ... In head and neck squamous cell carcinomas at least 15 DNA repair genes have frequently hypermethylated promoters; these genes ... Gagnon KT, Li L, Chu Y, Janowski BA, Corey DR (2014). "RNAi factors are present and active in human cell nuclei". Cell Rep. 6 ( ...
1992). "Neuronal-type nicotinic receptors in human neuroblastoma and small-cell lung carcinoma cell lines". FEBS Lett. 312 (1 ... Cell. Mol. Biol. (Noisy-le-grand). 43 (3): 433-42. PMID 9193799. Gerzanich V, Kuryatov A, Anand R, Lindstrom J (1997). ""Orphan ... subunits beta3 and beta4 and expression of seven nAChR subunits in the human neuroblastoma cell line SH-SY5Y and/or IMR-32". ... Nicotine Activity on Chromaffin Cells edit]] The interactive pathway map can be edited at WikiPathways: " ...
... melanoma and non-small cell lung carcinoma. Clinically BRMS1 expression correlates with survival in breast cancer and non-small ... High expression of CTGF is correlated with improved survival in colorectal cancer, non-small cell lung carcinoma and ... cell lung carcinoma. SDPR functions as a metastasis suppressor in breast cancer, potentially by priming cells to apoptosis. ... hepatocellular and non-small cell carcinoma. It affects the MAPK and cytoskeleton-organizing cellular pathways, which ...
The black arrows point to ferrugionous bodies that are located at the periphery of a focus of non-small cell lung carcinoma, ... "Asbestos content of lung tissue and carcinoma of the lung: a clinicopathologic correlation and mineral fiber analysis of 234 ... Figure B shows lungs with asbestos-related diseases, including pleural plaque, lung cancer, asbestosis, plaque on the diaphragm ... Lower RT/lung disease. (including LRTIs). Bronchial/. obstructive. acute. Acute bronchitis. chronic. COPD Chronic bronchitis. ...
Oral carcinoma[edit]. Patients after HSCT are at a higher risk for oral carcinoma. Post-HSCT oral cancer may have more ... Researchers have conducted small studies using non-myeloablative hematopoietic stem cell transplantation as a possible ... who have lost their stem cells after birth. Other conditions[13] treated with stem cell transplants include sickle-cell disease ... Peripheral blood stem cells[26] are now the most common source of stem cells for HSCT. They are collected from the blood ...
Anaplastic cells have lost total control of their normal functions and many have deteriorated cell structures. Anaplastic cells ... However, a smaller tumor in an area such as Wernicke's area (small area responsible for language comprehension) can result in a ... Brain metastasis in the right cerebral hemisphere from lung cancer, shown on magnetic resonance imaging. ... Anaplastic astrocytoma, Astrocytoma, Central neurocytoma, Choroid plexus carcinoma, Choroid plexus papilloma, Choroid plexus ...
BaP was shown to cause genetic damage in lung cells that was identical to the damage observed in the DNA of most malignant lung ... Thus, in most cases, small amounts of BaP are metabolized prior to being passed into the blood.[citation needed] The lungs are ... In the 18th century a scrotal cancer of chimney sweepers, the chimney sweeps' carcinoma, was already known to be connected to ... "Lung cancer as consequence by Benzopyrene in smokers". Lung Cancer. Archived from the original on April 14, 2005. Retrieved ...
Non-small-cell lung cancer. Over-expression. 29%. Immunohistochemistry. [22]. Soft tissue sarcoma. Over-expression. 95%. ... Esophageal squamous cell cancer. Over-expression. 47%. Immunohistochemistry. [24]. Renal cell carcinoma. Under-expression. 100% ... of non-small cell lung cancers,[45] and 36% of colon cancers.[46] miR-34a is also generally under-expressed in primary ... "High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients". Br. J. ...
Small intestine cancer. *Small-cell carcinoma. *Soft-tissue sarcoma. *Spinal tumor. *Squamous cell carcinoma ...
... and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells". Molecular Pharmacology. 75 (1): 196-207. ... produced by carcinoma cells, acts through paracrine signaling on endothelial cells and through autocrine signaling on carcinoma ... Paracrine signaling is a form of cell-cell communication in which a cell produces a signal to induce changes in nearby cells, ... These T cells can then go on to perform effector functions such as macrophage activation, B cell activation, and cell-mediated ...
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. In: The New England Journal of Medicine. Band ... Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III ... Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer ... EAU guidelines on renal cell carcinoma: the 2010 update. In: European Urology. Band 58, 2010, S. 398-406, doi:10.1016/j.eururo. ...
The common house mold, Trichoderma longibrachiatum, produces small toxic peptides containing amino acids not found in common ... This affects in the cells action potential profile, as seen in cardiomyocytes, pneumocytes and neurons leading to conduction ... "National Heart, Lung, and Blood Institute. October 1, 2010. Retrieved January 15, 2014.. ... "Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment". Environmental Health Perspectives. 118 (6): ...
"Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population". ... CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus ... Various types of CD30-positive T cell lymphomas[11]. *CD30-positive cases of the NK cell lymphoma, extranodal NK/T-cell ... "T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor ...
Small-cell carcinoma. *Transitional cell carcinoma. Penis. *Carcinoma *Extramammary Paget's disease. *Bowen's disease ... Stage 3 seminoma is characterized by the presence of metastasis outside the retroperitoneum-the lungs in "good risk" cases or ... A seminoma is a germ cell tumor of the testicle or, more rarely, the mediastinum or other extra-gonadal locations. It is a ... Weidner N (February 1999). "Germ-cell tumors of the mediastinum". Seminars in Diagnostic Pathology. 16 (1): 42-50. PMID ...
Treatment of renal cell carcinoma with infliximab resulted in prolonged disease stabilization in certain patients. Etanercept ... negative regulation of branching involved in lung morphogenesis. • JNK cascade. • death-inducing signaling complex assembly. • ... positive regulation of heterotypic cell-cell adhesion. • negative regulation of mitotic cell cycle. • endothelial cell ... but it is produced also by a broad variety of cell types including lymphoid cells, mast cells, endothelial cells, cardiac ...
For example: non-melanoma skin cancer, head and neck cancer, breast cancer, non-small cell lung cancer, cervical cancer, anal ... 2005). "Cervix carcinoma". In Gerbaulet A, Pötter R, Mazeron J, Limbergen EV. The GEC ESTRO handbook of brachytherapy. Belgium ... Targeting double-stranded breaks increases the probability that cells will undergo cell death. Cancer cells are generally less ... Fractionation allows normal cells time to recover, while tumor cells are generally less efficient in repair between fractions. ...
Virchow's cell, a macrophage in Hansen's disease. *Virchow's cell theory, omnis cellula e cellula - every living cell comes ... It is now believed that the Kaiser had hybrid verrucous carcinoma, a very rare form of verrucous carcinoma, and that Virchow ... Rudolph Leukart found that these tiny worms could develop into adult roundworms in the intestine of a dog. He correctly ... lung cancer. This has become known as Virchow's node and simultaneously Troisier's sign.[54][55] ...
squamous-cell carcinoma. *basal-cell carcinoma. *Merkel-cell carcinoma. *nevus sebaceous. *trichoepithelioma ... The word carbuncle is believed to have originated from the Latin: carbunculus, originally a small coal; diminutive of carbon-, ... The drainage of a lung abscess may be performed by positioning the patient in a way that enables the contents to be discharged ... The final structure of the abscess is an abscess wall, or capsule, that is formed by the adjacent healthy cells in an attempt ...
Originally started a laryngeal carcinoma strain, the cell line was contaminated and displaced by HeLa cells, and has now been ... The antigens of the anti-Sm antibodies are the core units of the small nuclear ribonucleoproteins (snRNPs), termed A to G, and ... They are associated with central nervous system involvement, kidney disease, lung fibrosis and pericarditis in SLE, but they ... T-cells and B-cells) and antigen presenting cells. These cells coordinate an immune response upon the detection of foreign ...
Small cell carcinoma is a very rare (1%[77]) type of prostate cancer that cannot be diagnosed using the PSA.[77][78] As of 2009 ... Further investigation with this substance revealed that it could interfere with the LT receptors in the lung carcinoma [38]. In ... Initially, small clumps of cancer cells remain confined to otherwise normal prostate glands, a condition known as carcinoma in ... "Small-cell carcinoma of the prostate". Journal of the Royal Society of Medicine. 90 (6): 340-1. PMC 1296316 . PMID 9227387.. ...
Celiac disease Ulcerative colitis Crohn's disease Hepatic cirrhosis Hepatocellular carcinoma Lung cancer, including small cell ... Mignogna MD, Fortuna G, Satriano AR (December 2008). "Small-cell lung cancer and necrolytic migratory erythema". The New ... Wilkinson DS (1973). "Necrolytic migratory erythema with carcinoma of the pancreas". Transactions of the St. John's Hospital ... swollen epidermal cells and necrosis of the superficial epidermis are most characteristic. Immunofluorescence is usually ...
... and died of complications from metastatic lung cancer (metastatic small cell neuroendocrine carcinoma). He was transported to ...
Non-small-cell lung carcinoma. *Squamous-cell carcinoma. *Adenocarcinoma (Mucinous cystadenocarcinoma). *Large-cell lung ... Histologically, it forms clusters of goblet cells containing mucin with a minor admixture of Paneth cells and endocrine cells. ... Goblet cell carcinoid[edit]. Main article: Goblet cell carcinoid. This is considered to be a hybrid between an exocrine and ... The term 'crypt cell carcinoma' has been used for them, and though perhaps more accurate than considering them carcinoids, has ...
Alox5 gene knockout mice exhibit an increase in the lung tumor volume and liver metastasis of Lewis lung carcinoma cells that ... mead acid metabolizing cells produce relatively little LTB3 and are blocked from metabolizing arachidonic acid to LTB4. On the ... In skin, Langerhans cells strongly express ALOX5. Fibroblasts, smooth muscle cells and endothelial cells express low levels of ... mast cells, dendritic cells, and B-lymphocytes express ALOX5. Platelets, T cells, and erythrocytes are ALOX5-negative. ...
"Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies", Lancet, 341 (8836): 21-22, doi: ... The purpose of this clinical case demonstrates the aggressive nature of the neuroendocrine small cell carcinoma with rapid ... a case report of Neuroendocrine Small Cell Carcinoma of the Endometrium presenting as Paraneoplastic Cushing's Syndrome". Facts ... In the case of paraneoplastic Cushing's syndrome arising from a small cel carcinoma of the endometrium, paraneoplastic syndrome ...
... (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC ... Large-cell lung carcinoma[edit]. Main article: Large-cell lung carcinoma. Large cell lung carcinoma (LCLC) is a heterogeneous ... using a uniform scheme for non-small cell lung carcinoma, small-cell lung carcinoma and broncho-pulmonary carcinoid tumors.[30] ... Non-Small Cell Lung Cancer at eMedicine *^ "What Is Non-Small Cell Lung Cancer?". www.cancer.org.. .mw-parser-output cite. ...
the salpingopalatine fold, a smaller fold, in front of the salpingopharyngeal fold, extending from the superior part of the ... and moisten air and conduct it into the lungs.[1]) The pharynx makes up the part of the throat situated immediately behind the ... the vertebrate pharynx is unique in that it gives rise to endoskeletal support through the contribution of neural crest cells.[ ... Nasopharyngeal carcinoma. *Pharyngeal aspiration. *Pharyngeal consonant. *Pharyngeal (disambiguation). *Saccopharynx, a genus ...
... used in the treatment of non-small-cell lung cancer[46][48][49]), vindesine, and vinflunine.[41] These drugs are cell cycle- ... "Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer". Clinical Medicine Insights: Oncology. 5: ... The most common medications affect mainly the fast-dividing cells of the body, such as blood cells and the cells lining the ... M - mitosis; where the cell divides to produce two daughter cells that continue the cell cycle. ...
These can include the bones, lungs, liver, and/or brain.[16]. Treatment[edit]. Surgery has traditionally played a limited role ... IBC makes up only a small percentage of breast cancer cases (1-6% in the USA[4]). IBC is often diagnosed in younger women ... It is characterised by the presence of cancer cells in the subdermal lymphatics on skin biopsy. Consequently, IBC is always ... Ductal carcinoma in situ (DCIS): Paget's disease of the breast. *Comedocarcinoma. *Invasive ductal carcinoma (IDC) ...
Promoter hypermethylation of MLH1 occurs in 48% of non-small-cell lung cancer squamous cell carcinomas. Promoter ... of non-small-cell lung cancers. Promoter hypermetylation of ATM occurs in 47% of non-small-cell lung cancers. ... In head and neck squamous cell carcinomas at least 15 DNA repair genes have frequently hypermethylated promoters; these genes ... doi:10.1016/j.cell.2011.04.024. PMID 21620139.. *^ Saxonov S, Berg P, Brutlag DL (2006). "A genome-wide analysis of CpG ...
"Itraconazole Inhibits Angiogenesis and Tumor Growth in Non-Small Cell Lung Cancer". Cancer Research. 71 (21): 6764-72. doi: ... Feb 2007). "Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions ... inhibit cell proliferation of endothelial cells. thrombospondin. inhibit cell migration, cell proliferation, cell adhesion and ... inhibit cell proliferation and induce apoptosis of endothelial cells. endostatin. inhibit cell migration, cell proliferation ...
... most often non-small-cell lung carcinoma (50 percent), small-cell lung carcinoma (25 percent), lymphoma, or metastasis, causing ... Dorsal root ganglion inflammation Small-cell lung cancer and, less often, cancer of the breast, colon or ovary may produce ... About 70 percent of breast and prostate cancer patients, and 40 percent of those with lung, kidney and thyroid cancers develop ... In breast, prostate or lung cancer, multiple myeloma and some other cancers, sudden onset limb or back pain may indicate ...
Micrograph of urethral cancer (urothelial cell carcinoma), a rare problem of the urethra. ... A small (1 or 2 cm) portion passing through the external urethral sphincter. This is the narrowest part of the urethra. It is ... It also serves as a passage for urine to flow.[1] Urine typically contains epithelial cells shed from the urinary tract. Urine ... The epithelium of the urethra starts off as transitional cells as it exits the bladder. Further along the urethra there are ...
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC ... Large-cell lung carcinoma[edit]. Main article: Large-cell lung carcinoma. Large cell lung carcinoma (LCLC) is a heterogeneous ... using a uniform scheme for non-small cell lung carcinoma, small-cell lung carcinoma and broncho-pulmonary carcinoid tumors.[30] ... Non-Small Cell Lung Cancer at eMedicine *^ "What Is Non-Small Cell Lung Cancer?". www.cancer.org.. .mw-parser-output cite. ...
... Daniel J. Oh,1 Ellen Dinerman,1 Andrew H. Matthews,1 Abraham W. ... She was later diagnosed with small cell carcinoma of the lung. Conclusions. In this case report, we describe a critically ill ... However, its presence in solid tumors such as small cell carcinoma of the lung has been reported rarely [1-5]. Even fewer cases ... "Small cell lung cancer accompanied by lactic acidosis and syndrome of inappropriate secretion of antidiuretic hormone," Lung ...
Non-Small Cell Lung CarcinomaA Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better ... Non-Small Cell Lung CarcinomaTrial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer NCT00321308 ... Non-Small Cell Lung CarcinomaEvaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The ... Non-Small Cell Lung CarcinomaPH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line ...
Pfizer is currently recruiting for the NCT03052608 Non-Small-Cell Lung Carcinoma Cancer trial. Review trial description, ...
Diseases : Carcinoma: Non-Small-Cell Lung, Carcinoma: Small Cell Lung, Lung Cancer, Lung Cancer: Metastatic ... Diseases : Carcinoma: Small Cell Lung, Colon Cancer, Lung Cancer, Nasopharyngeal Cancer. Pharmacological Actions : Anti- ... Ganoderma is cytotoxic to both drug-sensitive and drug-resistant small-cell lung carcinoma cells and can reverse resistance to ... Diseases : Carcinoma: Small Cell Lung, Nicotine/Tobacco Toxicity Pharmacological Actions : Angiogenesis Inhibitors, Anti- ...
Histologically, this type has sheets of highly atypical cells with focal... more ... of lung cancers, typically manifesting as a large peripheral mass on chest radiograph. ... Drugs & Diseases , Oncology , Non-Small Cell Lung Cancer (NSCLC) Q&A How is large-cell carcinoma subtype of non-small cell lung ... Non-small cell lung cancer. Left pleural effusion and volume loss secondary to non-small cell carcinoma of the left lower lobe ...
Diseases : Lung Cancer, Non-Small-Cell Lung Carcinoma. Pharmacological Actions : Antineoplastic Agents, Apoptotic, Cell cycle ... Diseases : Lung Cancer, Non-Small-Cell Lung Carcinoma. Pharmacological Actions : Anti-metastatic, Antiproliferative , Cell ... Diseases : Cancers: Drug Resistant, Lung Cancer, Non-Small-Cell Lung Carcinoma. Pharmacological Actions : Apoptotic, Cell cycle ... Diseases : Lung Cancer, Non-Small-Cell Lung Carcinoma. Pharmacological Actions : Anti-Inflammatory Agents, Anti-metastatic, ...
Expression of neurophysin-related precursor in cell membranes of a small-cell lung carcinoma. L C Rosenbaum, E A Neuwelt, H H ... Expression of neurophysin-related precursor in cell membranes of a small-cell lung carcinoma ... Expression of neurophysin-related precursor in cell membranes of a small-cell lung carcinoma ... Expression of neurophysin-related precursor in cell membranes of a small-cell lung carcinoma ...
... the dependence of non-small cell lung carcinomas (NSCLC) for HH activity had not been comprehensively studied. During a screen ... of a panel of 60 human tumor cell lines with an HH antagonis … ... pathway might be activated in some lung tumors, ... Frequent requirement of hedgehog signaling in non-small cell lung carcinoma Oncogene. 2007 Feb 15;26(7):1046-55. doi: 10.1038/ ... the dependence of non-small cell lung carcinomas (NSCLC) for HH activity had not been comprehensively studied. During a screen ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canadas national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc. ...
One hundred forty-eight patients with small cell carcinoma of the lung had und … ... In an attempt to define the role of initial surgical resection in patients with undifferentiated small cell carcinoma of the ... lung, we reviewed the experience of the Veterans Administration Surgical Oncology Group (VASOG). ... Surgical resection in the management of small cell carcinoma of the lung J Thorac Cardiovasc Surg. 1982 Oct;84(4):481-8. ...
Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY). The safety and scientific validity of this study is the ... Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thromb Res ...
... invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell ... lung carcinomas (NSCLC) and certain other human carcinomas. ... cultured cells from a non-small cell lung carcinoma, and (3) ... human lung carcinoma cells from pleural effusions or cultured cells from human non-small cell lung carcinoma, or cells from a ... Lung Carcinoma. Adeno 18/19. Squamous 8/10. Small Cell 2/6. Large Cell 2/2. Breast Carcinoma 13/16. Colon Carcinoma 9/9. ...
... little is known about how to prevent it. Recently this type of lung cance ... Because little is known about the actual cause of bronchoalveolar carcinoma, ... Non-Small Cell Lung Cancer. The most common type of lung cancer, non-small cell lung cancer (NSCLC) affects tens of thousands ... Continue Learning about Non-Small Cell Lung Cancer. Treating Non-Small Cell Lung Cancer with Immunotherapy ...
Lung Small Cell Carcinoma Description SK-LC-13 is a human lung cancer cell line. Source This cell line was established from a ... lung metastasis from a person with lung small cell carcinoma. ... Tissue of Origin: Lung. Cancer Type: Lung Small Cell Carcinoma ... This cell line was established from a lung metastasis from a person with lung small cell carcinoma. ... SK-LC-13 is a human lung cancer cell line.. Source. ... This cell line may be licensed nonexclusively for research or ...
Carcinoma, Non-Small-Cell Lung. Carcinoma, Bronchogenic. Bronchial Neoplasms. Lung Neoplasms. Respiratory Tract Neoplasms. ... Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma. The safety and scientific validity of ... to all sites of oligoprogressive disease in patients with metastatic non-small cell lung carcinoma who have progressed through ... Non Small Cell Lung Cancer Oligoprogressive Radiation: Local consolidative radiation therapy Drug: Standard of care radiation ...
It can inhibit the growth and induce morphological changes of NSCLC cells in gene transfection studies. To explore the ... gene is a recently identified tumor suppressor gene for human non-small cell lung carcinoma (NSCLC). ... DLC-1 tumor supressor gene induces apoptosis in human non-small cell lung carcinoma cells following a unique process of cell ... Carcinomas; Cell-growth; Microscopy; Genes; Tumorigens; Tumorigenesis; Gene-mutation; Liver-cells; Lung-cells ...
... to the process of tumor development was used in this study by examining the gene expression profile in human lung cancer cells ... Cell-function; Cell-growth; Cell-metabolism; Cell-transformation; Cellular-uptake; Lung-cancer; Lung-cells; Lung-disease; ... Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-aza-2 -deoxycytidine.. ... A cDNA array analysis was carried out on 5-aza-dC-treated and untreated non small cell lung cancer (NSCLC) cell line NCI-H522. ...
Learn more about Non-small Cell Lung Carcinoma from related diseases, pathways, genes and PTMs with the Novus Bioinformatics ... non-small cell lung cancer (disorder), carcinoma, non-small-cell lung, carcinoma non-small cell lung, carcinoma of lung. ... Non-small Cell Lung Carcinoma is also known as non-small cell lung carcinoma, nonsmall cell lung cancer, nsclc, ... Non-small Cell Lung Carcinoma: Disease Bioinformatics. Research of Non-small Cell Lung Carcinoma has been linked to Malignant ...
... together with the large cell neuroendocrine carcinoma (LCNEC), typical carcinoid (TC), and atypical carcinoid (AC) make a group ... cell morphology; small cell lung carcinoma; neuroendocrine carcinoma; non-small cell lung carcinoma; bronchoscopy; Kaplan Meier ... Small cell carcinoma of the lung (SCLC) together with the large cell neuroendocrine carcinoma (LCNEC), typical carcinoid (TC), ... Miličić V, Prvulović I, Mišić M, Perić M, Samardžić S, Tomić K. Value of Cytology in Small Cell Lung Carcinoma Diagnostic - ...
Towards personalized treatment in non-small-cell lung carcinoma. Alvaro Martinez Mesa, Nuria Reina Marfil, Eva Cabrera Cesar, ... Towards personalized treatment in non-small-cell lung carcinoma. Alvaro Martinez Mesa, Nuria Reina Marfil, Eva Cabrera Cesar, ... Towards personalized treatment in non-small-cell lung carcinoma. Alvaro Martinez Mesa, Nuria Reina Marfil, Eva Cabrera Cesar, ... Towards personalized treatment in non-small-cell lung carcinoma Message Subject (Your Name) has sent you a message from ...
Lung Neoplasms. Small Cell Lung Carcinoma. Carcinoma, Neuroendocrine. Carcinoma. Neoplasms, Glandular and Epithelial. Neoplasms ... SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma. The safety and scientific validity of this study is ... Part 1A is a dose escalation study in patients with small cell lung cancer or large cell neuroendocrine carcinoma with ... Genetics Home Reference related topics: Lung cancer Genetic and Rare Diseases Information Center resources: Small Cell Lung ...
... lung carcinomas are divided into 8 major taxa: Squamous cell carcinoma Small cell carcinoma Adenocarcinoma Large cell carcinoma ... Combined small cell lung carcinoma (or c-SCLC, and rarely rendered as "small-cell lung carcinoma") is a form of multiphasic ... December 2007). "Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation". Lung Cancer. ... December 1982). "The clinical behavior of "mixed" small cell/large cell bronchogenic carcinoma compared to "pure" small cell ...
Non-small Cell Carcinoma ) on www.antikoerper-online.... , Jetzt Produkt ABIN2456034 bestellen. ... Find and order tissues and products like this Lung Tissue Slide ( ... Non-small Cell Carcinoma ) Lung Tissue Slide (Non-small Cell ... Lung Produktmerkmale Preparation: The single tissue slides contain 4 μm sections of formalin-fixed, paraffin-embedded human ... Tissue or Cell type Lung Bestandteile Lung Tissue Slide (Non-small Cell Carcinoma ) ...
HomeIndustry SolutionsOncologyPreclinicalCell LinesNCI-H23: Human Non-Small Cell Lung Carcinoma ... Biologics SolutionsBiomarkersSmall Molecule SolutionsBiosimilars Development SolutionsCell & Gene Therapy Solutions ... Please note that cell lines are not for sale and unavailable for purchase from Covance.*** ... Cell LinesTumor ModelsCAR TIn VitroTumor SpotlightsPosters Choose Subcategory. Cell Lines. Tumor Models. CAR T. In Vitro. Tumor ...
... but these mutations have rarely been reported in small cell lung carcinoma (SCLC). Combined SCLC is rare, and the EGFR mutation ... receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung.. ... In lung cancer, somatic mutations of epidermal growth factor receptor (EGFR) are concentrated in exons 18-21, especially in ... In addition to the clinicopathological characteristics of this rare histological type of lung cancer, these findings provide ...
... in non-small cell lung carcinomas. Lung Cancer. 61:163-169. 2008. View Article : Google Scholar : PubMed/NCBI ... The ALK fusion gene is a key oncogenic driver in a subset of patients with non-small cell lung carcinomas (NSCLCs) (1-5). EML4- ... Detection of CD74-ROS1 fusion transcripts in a non-small cell lung carcinoma (NSCLC). (A) cDNA derived from cancerous tissue of ... The recent discovery of fusion oncokinases in a subset of non-small cell lung carcinomas (NSCLCs) is of considerable clinical ...
... conjugate NaPi2B was well tolerated with no dose-limiting toxicities in patients with ovarian cancer and non-small cell lung ... Novel Drug Well Tolerated in Patients With Ovarian Carcinoma, Non-Small Cell Lung Cancer. ... conjugate NaPi2B was well tolerated with no dose-limiting toxicities in patients with ovarian cancer and non-small cell lung ... XMT-1536 is a transmembrane sodium-phosphate transporter that is expressed in ovarian carcinoma and NSCLC, as well as other ...
  • Non-small-cell lung carcinoma ( NSCLC ) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). (wikipedia.org)
  • NSCLC accounts for about 85% of all lung cancers. (wikipedia.org)
  • The most common types of NSCLC are squamous cell carcinoma , large cell carcinoma , and adenocarcinoma , but there are several other types that occur less frequently. (wikipedia.org)
  • [5] Non-squamous cell carcinoma almost occupy the half of NSCLC. (wikipedia.org)
  • Lung cancer in people who have never smoked is almost universally NSCLC, with a sizeable majority being adenocarcinoma. (wikipedia.org)
  • On relatively rare occasions, malignant lung tumors are found to contain components of both SCLC and NSCLC. (wikipedia.org)
  • LCLC's have typically comprised around 10% of all NSCLC in the past, although newer diagnostic techniques seem to be reducing the incidence of diagnosis of "classic" LCLC in favor of more poorly differentiated squamous cell carcinomas and adenocarcinomas. (wikipedia.org)
  • AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC). (pfizer.com)
  • Patients with mixed NSCLC with predominantly squamous cell carcinoma should be classified as squamous and thus do not qualify for this study. (pfizer.com)
  • NSCLC that cannot be classified as one of the eligible histologies (adenocarcinoma, large cell or bronchioalveolar). (pfizer.com)
  • How is large-cell carcinoma subtype of non-small cell lung cancer (NSCLC) characterized? (medscape.com)
  • Although it had previously been suggested that the hedgehog (HH) pathway might be activated in some lung tumors, the dependence of non-small cell lung carcinomas (NSCLC) for HH activity had not been comprehensively studied. (nih.gov)
  • During a screen of a panel of 60 human tumor cell lines with an HH antagonist, we observed that the proliferation of a subset of NSCLC cell lines was inhibited. (nih.gov)
  • These NSCLC cell lines express HH, as well as key HH target genes, consistent with them being activated through an autocrine mechanism. (nih.gov)
  • Interestingly, we also identified a number of NSCLC cell lines that express high levels of the downstream transcription factor GLI1 and harbor enhanced levels of HH activity, but appear insensitive to known HH antagonists. (nih.gov)
  • The present invention is concerned with novel monoclonal antibodies which define a glycolipid antigen associated with human non-small cell lung carcinomas ("NSCLC") and certain other human carcinomas. (freepatentsonline.com)
  • The antibodies find use in diagnostic methods such as the detection of malignant cells associated with NSCLC and in therapeutic methods. (freepatentsonline.com)
  • The most common type of lung cancer, non-small cell lung cancer (NSCLC) affects tens of thousands of people each year. (sharecare.com)
  • With three primary types of NSCLC, this disease accounts for about 80% of all lung cancer, the deadliest type of cancer in the U.S. among both men and women. (sharecare.com)
  • Adenocarcinoma, the most common form of NSCLC, typically develops in the outer portion of our lungs. (sharecare.com)
  • The deleted in liver cancer (DLC-1) gene is a recently identified tumor suppressor gene for human non-small cell lung carcinoma (NSCLC). (cdc.gov)
  • It can inhibit the growth and induce morphological changes of NSCLC cells in gene transfection studies. (cdc.gov)
  • A cDNA array analysis was carried out on 5-aza-dC-treated and untreated non small cell lung cancer (NSCLC) cell line NCI-H522. (cdc.gov)
  • Among them, downregulation of tyrosine protein kinase ABL2 (ABL2) gene and upregulation of hint/protein kinase C inhibitor 1 (Hint/PKCI-1), DVL1, TIMP-1, and TRP-1 genes were found in expanded observations in two or three of five 5-aza-dC-treated NSCLC cell lines. (cdc.gov)
  • Among these genes, we found that cDNA transfer of Hint/PKCI-1 resulted in a significant in vitro growth inhibition in two cell lines exhibiting 5-aza-dC-induced upregulation of Hint/PKCI-1 and significantly reduced in vivo tumorigenicity of one NSCLC cell line. (cdc.gov)
  • Non-small Cell Lung Carcinoma is also known as non-small cell lung carcinoma, nonsmall cell lung cancer, nsclc, non-small cell lung cancer (disorder), carcinoma, non-small-cell lung, carcinoma non-small cell lung, carcinoma of lung. (novusbio.com)
  • 78.28% (292) were non-small-cell lung carcinoma (NSCLC) of which 59.58% (174) had a study of markers being 35.05 positive (61). (ersjournals.com)
  • Nonsquamous-cell carcinoma almost occupies the half of NSCLC. (wikipedia.org)
  • Combined small cell lung carcinoma (or c-SCLC, and rarely rendered as "small-cell lung carcinoma") is a form of multiphasic lung cancer that is diagnosed by a pathologist when a malignant tumor arising from transformed cells originating in lung tissue contains a component of small cell lung carcinoma (SCLC) admixed with one (or more) components of non-small cell lung carcinoma (NSCLC). (wikipedia.org)
  • In most cases of c-SCLC, genomic and immunohistochemical studies suggest that the morphological divergence of the separate components occurs when a SCLC-like cell is transformed into a cell with the potential to develop NSCLC variant characteristics, and not vice versa. (wikipedia.org)
  • Recently, crizotinib, a small molecule inhibitor of ALK, was shown to selectively inhibit the growth of ALK-positive NSCLC ( 6 - 8 ), indicating that a subclass of NSCLC patients are likely to benefit clinically from an ALK inhibitor. (spandidos-publications.com)
  • However, since the incidence of ROS1 or RET fusions is less than that of ALK fusions in NSCLC, only a small number of NSCLC patients with ROS1 or RET fusions has thus far been identified. (spandidos-publications.com)
  • XMT-1536, a first-in-class antibody-drug conjugate NaPi2B was well tolerated with no dose-limiting toxicities in patients with ovarian cancer and non-small cell lung cancer (NSCLC). (pharmacytimes.com)
  • XMT-1536 is a transmembrane sodium-phosphate transporter that is expressed in ovarian carcinoma and NSCLC, as well as other tumors. (pharmacytimes.com)
  • The study is currently enrolling for dose expansion in patients with high-grade serous ovarian carcinoma and NSCLC, adenocarcinoma subtype. (pharmacytimes.com)
  • The May edition of the Journal of Thoracic Oncology features a study aimed to clarify expression patterns of a novel cancer biomarker, CD24, in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance status, age, gender and prognostic significance. (scienceblog.com)
  • NSCLC (includes squamous, large cell or adenocarcinoma). (knowcancer.com)
  • Chromosome band 9p21 is deleted frequently in non-small cell lung carcinoma (NSCLC), and the p15 and p16 cyclin-dependent kinase-4 inhibitor genes map within this deletion region. (aacrjournals.org)
  • Recent studies demonstrated deletion of p15 and p16 in NSCLC metastases and cell lines, suggesting a role for these genes in NSCLC progression. (aacrjournals.org)
  • Retinoblastoma (RB) protein expression was examined in paraffin and frozen tissue sections of 36 primary non-small cell lung carcinomas (NSCLC) using immunohistochemistry with confirmation by direct Western blotting. (aacrjournals.org)
  • MET, EGFR, and their interaction in NSCLC cell lines. (aacrjournals.org)
  • A, MET and EGFR are coexpressed in a high percentage of NSCLC cell lines. (aacrjournals.org)
  • SGX523 sensitized NSCLC cells to erlotinib in suppressing proliferation in the presence of MET and EGFR ligands in vitro . (aacrjournals.org)
  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are current standard of care for patients with EGFR mutation and metastatic non-small-cell lung carcinoma (NSCLC), but most patients using EGFR TKIs acquire resistance later. (selleckchem.com)
  • Knockdown of BTK sensitized the NSCLC cells to Gefitinib. (selleckchem.com)
  • Meanwhile, the second-generation BTK inhibitor Acalabrutinib effectively suppressed SOX2, STAT3/JAK2/Akt axis and potentiated the anti-proliferative effect of Gefitinib and Osimertinib in NSCLC cells, including the T790M H1975 cells. (selleckchem.com)
  • Our findings suggested that BTK mediates stemness and EMT properties, and inhibition of BTK potentiates the effect of Gefitinib and Osimertinib in NSCLC cells resistant to TKI. (selleckchem.com)
  • However, the syndrome of inappropriate anti-diuretic hormone secretion (SIADH) is rare in non-small cell lung cancer (NSCLC). (ecancer.org)
  • Parathyroid hormone-related protein (PTHrP) is commonly expressed in non-small cell lung carcinomas (NSCLC). (aacrjournals.org)
  • Because roughly two thirds of non-small cell lung cancers (NSCLC) express PTHrP regardless of histology ( 20 ), the protein could be important in the pathophysiology of the disease beyond its role in causing hypercalcemia. (aacrjournals.org)
  • Hence, the goal of this project was to conduct a large patient study to determine whether survival of patients with NSCLC varied based on tumor PTHrP expression and to examine the influence of PTHrP with other factors known to affect patient life span in lung cancer. (aacrjournals.org)
  • The possible involvement of estrogen receptors (ERs) and testicular orphan nuclear receptors (TRs) in human non-small cell lung carcinoma (NSCLC) has been suggested, but their precise roles and their relationship remain largely unknown. (spandidos-publications.com)
  • We used tissue microarrays including NSCLC tissues (n=154) and negative controls (n=14) to examine the expression of TRA16 and ERβ, and in vitro reporter gene assays, the mammalian two-hybrid method and immunoprecipitation in Cos-1 cells to investigate the relationships among TRA16, ERβ and TR2. (spandidos-publications.com)
  • Our findings demonstrate that TRA16 could be a promising diagnostic and prognostic biomarker in NSCLC, and promotes cancer cell growth through activation of the ERβ pathway by interacting with ERβ and TR2. (spandidos-publications.com)
  • Niikawa et al first reported that intratumoral estradiol (an activator of ERβ) concentration was significantly higher than that of corresponding non-neoplastic lung tissues, and positively associated with tumor size and Ki-67 labeling index (LI) in ER-positive NSCLC tissues ( 8 ). (spandidos-publications.com)
  • To identify the pattern of IRAK-1 protein expression in non-small cell lung carcinoma (NSCLC) and corresponding preneoplastic lesions. (pubmedcentralcanada.ca)
  • IRAK-1 is frequently expressed in NSCLC tissue specimens, and this expression is an early phenomenon in the sequential development of lung cancer. (pubmedcentralcanada.ca)
  • the two most common NSCLC histologic types are squamous cell carcinoma (SCC) and adenocarcinoma (ADCA) ( 2 ). (pubmedcentralcanada.ca)
  • Both NSCLC histologic types are believed to arise after a sequential progression of premalignant lesions, which include bronchial squamous metaplasias and dysplasias for squamous cell carcinoma, and peripheral atypical alveolar hyperplasias (AAH) for a subset of adenocarcinomas ( 3 ). (pubmedcentralcanada.ca)
  • Attending the seminar, Dr Basma M'Barek, Hy Vong Cancer Care Centre from FV Hospital, shared her experiences on the topic Optimizing When Using Osimertinib in Treating Non-Small-Cell Lung Carcinoma NSCLC & Sharing Treated Cases . (fvhospital.com)
  • our earlier studies had shown that reported ID1 is induced by nicotine or EGF stimulation of non-small cell lung cancer (NSCLC) cells and its down regulation abrogates cell proliferation, invasion and migration. (springer.com)
  • A microarray analysis was done on two different NSCLC cell lines (A549 and H1650) that were transfected with a siRNA to ID1 or a control, non-targeting siRNA. (springer.com)
  • STMN3 and GSPT1 were found to facilitate the proliferation, invasion and migration of NSCLC cells in response to nAChR activation. (springer.com)
  • Compared to non-small cell lung cancer (NSCLC), SCLC is generally more aggressive, with decreased doubling times and faster growth rates. (biomedcentral.com)
  • Aberrant signalling of receptor tyrosine kinases (RTKs), such as c-Met, the receptor for hepatocyte growth factor (HGF), has been implicated in the oncogenesis of various tumours including non-small cell lung carcinoma (NSCLC). (biologists.org)
  • This finding was confirmed in several NSCLC cell lines as well as in HeLa cells. (biologists.org)
  • This prospective observational study estimated the effect of prognostic factors, particularly continued smoking during therapy, on survival in advanced non-small cell lung cancer (NSCLC) patients receiving gemcitabine-platinum. (jcancer.org)
  • Lung cancer is one of the leading causes of cancer-related deaths worldwide [ 1 - 2 ], with non-small cell lung cancer (NSCLC) representing approximately 75%-85% of all types of lung cancer [ 3 ]. (jcancer.org)
  • Smoking is the single most important cause of NSCLC [ 5 - 8 ], with approximately 85% of human lung cancers arising in current or former smokers. (jcancer.org)
  • However, the immunological profile of non-small cell lung carcinoma (NSCLC) treated with neoadjuvant chemotherapy (NCT) is not yet fully characterized, and it may be therapeutically important. (deepdyve.com)
  • The MAGE-A3 cancer/testis antigen is frequently expressed in non-small cell lung cancer (NSCLC) and vaccination with MAGE-A3 in patients with MAGE-A3-positive NSCLC has shown promising results. (biomedcentral.com)
  • However, little is known about the expression of other cancer/testis antigens in NSCLC. (biomedcentral.com)
  • Tumor biopsies from normal lung tissue and from a large cohort (n = 169) of NSCLC patients were examined for GAGE, NY-ESO-1 and SP17 protein expression by immunohistochemical analysis. (biomedcentral.com)
  • Non-small cell lung cancer (NSCLC) accounts for more than 85% of new cases of lung cancer, which is the leading cause of cancer deaths worldwide [ 7 ], highlighting the need for novel therapeutic strategies for treatment of this disease. (biomedcentral.com)
  • Subsequently, for advanced nonsquamous cell nonsmall cell lung carcinoma (NSCLC) patients, predictive analyses on epidermal growth factor receptor, anaplastic lymphoma kinase and ROS1 are required. (ersjournals.com)
  • Until the arrival of pemetrexed, a relatively simple distinction between small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC) was sufficient to guide systemic treatment, and a meta-analysis of four different platinum doublets showed that none offered a significant advantage over the others in the treatment of advanced NSCLC [ 1 ]. (ersjournals.com)
  • As a result, the pathological diagnosis of lung cancer has become a multistep process, beginning with morphology and immunohistochemistry (IHC) to discriminate benign from malignant process, metastases from primary lung cancer and small cell lung carcinoma and NSCLC. (ersjournals.com)
  • BACKGROUND: Non-small cell lung carcinoma (NSCLC) is a complex malignancy that owing to its heterogeneity and poor prognosis poses many challenges to diagnosis, prognosis and patient treatment. (ox.ac.uk)
  • Here we present a genome-wide DNA methylation analysis of NSCLC samples and paired lung tissues, where we combine MethylCap and next generation sequencing (MethylCap-seq) to provide comprehensive DNA methylation maps of the tumor and paired lung samples. (ox.ac.uk)
  • We also identified DMRs that were specific to two of the major subtypes of NSCLC, adenocarcinomas and squamous cell carcinomas. (ox.ac.uk)
  • CONCLUSIONS: Collectively, we provide a resource containing genome-wide DNA methylation maps of NSCLC and their paired lung tissues, and comprehensive lists of known and novel DMRs and associated genes in NSCLC. (ox.ac.uk)
  • Non-small-cell lung carcinomas (NSCLC) are the most common form and account for around 85 - 90% of total lung cancers. (images.md)
  • ALK gene rearrangements in advanced non-small cell lung carcinomas (NSCLC) are an indication for targeted therapy with crizotinib. (elsevier.com)
  • The aim of this study was to perform a systematic review of the MEDLINE literature on the prognostic significance of these histopathological markers in patients with non-small cell lung carcinoma (NSCLC). (springeropen.com)
  • Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. (nih.gov)
  • Recent large scale genomic studies from the Clinical Lung Cancer Genome Project have identified different driver gene mutations in the subtypes of non-small cell lung carcinoma (NSCLC). (nih.gov)
  • These findings not only lead to remarkable progress in targeted therapies for lung cancer patients, but also provide fundamental knowledge for the subclassification of NSCLC. (nih.gov)
  • These guidelines emphasize: (1) the subclassification of NSCLC, (2) the critical role of molecular characterization of tumors for targeted therapy, (3) the unique terminology for subclassifying NSCLC using small biopsy specimens, and (4) the utility of IHC biomarkers in the accurate diagnosis and subclassification of lung cancer. (nih.gov)
  • In this review, we summarize the current WHO guidelines for the classification of lung cancer, discuss advancements of targeted therapy and immunotherapy, and address the utility and limitation of immunomarkers in the subclassification of NSCLC, as well as the prospective future of the field. (nih.gov)
  • To study expression of Anaplastic Lymphoma Kinase (ALK)and Epidermal Growth Factor Receptor (EGFR) mutations in patients of Non-Small Cell Lung Cancer NSCLC, that are the targets for specific ALK inhibitors and EGFR tyrosine kinase inhibitors. (jcdr.net)
  • Total 69 cases of histologically diagnosed NSCLC were examined retrospectively for immunohistochemical expression of EGFR and ALK, along with positive control of normal placental tissue and anaplastic large cell lymphoma respectively. (jcdr.net)
  • OBJECTIVE To study the association between HAb18G expression, tumor parameters, metastatic potential and prognosis in non-small cell lung carcinoma (NSCLC). (semanticscholar.org)
  • EGF-stimulated EGFR phosphorylation induced S100A2 expression and further activated E1A expression of Ad/SA, which was restored by EGFR signal inhibition in a concentration-dependent manner in non-small-cell lung carcinoma (NSCLC). (elsevier.com)
  • Patients treated with nivolumab for advanced non-small cell lung carcinoma (NSCLC) had a better survival rate at five years than those who received chemotherapy, a follow-up trial has shown [1] . (pharmaceutical-journal.com)
  • Checkmate 017 and [Checkmate] 057 are the first phase III trials to report five-year outcomes for a [programmed cell-death protein 1 (PD-1)] inhibitor in previously treated advanced NSCLC," said Scott Gettinger, professor of internal at Yale Comprehensive Cancer Center, Connecticut, and lead author of the study. (pharmaceutical-journal.com)
  • Adenocarcinoma of the lung is currently the most common type of lung cancer in "never smokers" (lifelong non-smokers). (wikipedia.org)
  • Historically, adenocarcinoma was more often seen peripherally in the lungs than small cell lung cancer and squamous cell lung cancer, both of which tended to be more often centrally located. (wikipedia.org)
  • It is closely correlated with a history of tobacco smoking , more so than most other types of lung cancer . (wikipedia.org)
  • [13] LCLC is, in effect, a "diagnosis of exclusion", in that the tumor cells lack light microscopic characteristics that would classify the neoplasm as a small-cell carcinoma, squamous-cell carcinoma, adenocarcinoma, or other more specific histologic type of lung cancer. (wikipedia.org)
  • Small cell or carcinoid lung cancer patients are also ineligible. (pfizer.com)
  • Serum IL-23 levels are elevated in lung cancer patients. (greenmedinfo.com)
  • The median survival time of patients in the deuterium depleted water consuming group was 2-4 times longer than it is generally observed in lung cancer patients. (greenmedinfo.com)
  • Siberian ginseng extracts had atiproliferative activity on various cancer and normal cell lines. (greenmedinfo.com)
  • Guideline] Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. (medscape.com)
  • Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. (medscape.com)
  • Potentially curative radiotherapy for non-small-cell lung cancer in Norway: a population-based study of survival. (medscape.com)
  • Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. (medscape.com)
  • Nonfilter and filter cigarette consumption and the incidence of lung cancer by histological type in Japan and the United States: analysis of 30-year data from population-based cancer registries. (medscape.com)
  • Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. (medscape.com)
  • Nelson R. Lung Cancer Rates Surging in Never-Smokers. (medscape.com)
  • Epidemiology and etiology of lung cancer. (medscape.com)
  • Alcohol consumption and lung cancer risk in never smokers: a meta-analysis. (medscape.com)
  • Ginsberg RJ, Vokes EE, Raben A. Non-small cell lung cancer. (medscape.com)
  • Exposure to environmental tobacco smoke and the risk of lung cancer: a meta-analysis. (medscape.com)
  • Spontaneous regression of metastatic squamous cell lung cancer. (greenmedinfo.com)
  • Citrus reticulata peel oil inhibits non-small cell lung cancer cell proliferation. (greenmedinfo.com)
  • Shikonin could be a novel therapeutic strategy against non-small cell lung cancer. (greenmedinfo.com)
  • Recently this type of lung cancer has been increasingly diagnosed in non-smoking women as well as people with Asian descent. (sharecare.com)
  • However, there are several preventable factors that are known play a role in developing other types of lung cancer. (sharecare.com)
  • In order to prevent lung cancer, doctors usually recommend that people avoid cigarette smoke (both first-hand and second-hand), exercise frequently, and eat a healthy diet. (sharecare.com)
  • Immunotherapies are a category of cancer drugs that work by helping the body's immune system identify and destroy cancer cells. (sharecare.com)
  • What are the different types of non-small cell lung cancer? (sharecare.com)
  • How can I prepare for an appointment for non-small cell lung cancer? (sharecare.com)
  • Although smoking is the primary cause of lung cancer, other risk factors include exposure to radon gas and asbestos. (sharecare.com)
  • Previous radiation therapy and a family or personal history of lung cancer also increases your risk. (sharecare.com)
  • A new approach in identifying alterations of genes that might be relevant to the process of tumor development was used in this study by examining the gene expression profile in human lung cancer cells exposed to 5-aza-2'-deoxycytidine (5-aza-dC). (cdc.gov)
  • Median survival in the group of patients with histologically confirmed small cell cancer was 238 days, for women 250 days, and for men 237 days. (srce.hr)
  • Personalized medicine is key to deciding the optimal treatment for a patient with lung cancer. (ersjournals.com)
  • In recent years, biomolecular markers have been discovered that have allowed increasing the therapeutic against lung cancer, especially in advanced stages. (ersjournals.com)
  • This is a Phase 1a/1b study of SC-002 in patients with relapsed small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). (clinicaltrials.gov)
  • Part 1A is a dose escalation study in patients with small cell lung cancer or large cell neuroendocrine carcinoma with cytologically confirmed, limited or extensive SCLC or LCNEC that have relapsed or refractory limited or extensive disease following no more than 2 prior chemotherapy regimens. (clinicaltrials.gov)
  • Adenocarcinoma of the lung is currently the most common type of lung cancer in "never smokers" (lifelong nonsmokers). (wikipedia.org)
  • Smoking is by far the leading risk factor for lung cancer. (wikipedia.org)
  • Lung cancer is a large and exceptionally heterogeneous family of malignancies. (wikipedia.org)
  • Over 50 different histological variants are explicitly recognized within the 2004 revision of the World Health Organization (WHO) typing system ("WHO-2004"), currently the most widely used lung cancer classification scheme. (wikipedia.org)
  • However, since different forms of malignant tumors generally exhibit diverse genetic, biological, and clinical properties - including response to treatment - accurate classification of lung cancer cases are critical to assuring that patients with lung cancer receive optimum management. (wikipedia.org)
  • Under WHO-2004, lung carcinomas are divided into 8 major taxa: Squamous cell carcinoma Small cell carcinoma Adenocarcinoma Large cell carcinoma Adenosquamous carcinoma Sarcomatoid carcinoma Carcinoid tumor Salivary gland-like carcinoma SCLC is generally considered to be the most aggressive of these major forms of lung cancer, with the worst long term prognosis and survival rates. (wikipedia.org)
  • It is currently thought that most cases of lung cancer probably occur after damage to genomic DNA causes malignant transformation of a single multipotent cell. (wikipedia.org)
  • This newly formed entity, sometimes referred to as a cancer stem cell, then begins to divide uncontrollably, giving rise to new daughter cancer cells in an exponential (or near exponential) fashion. (wikipedia.org)
  • The histogenesis of c-SCLC and other multiphasic forms of lung cancer appear to be complex and varied phenomena. (wikipedia.org)
  • In lung cancer, somatic mutations of epidermal growth factor receptor (EGFR) are concentrated in exons 18-21, especially in adenocarcinoma (Ad), but these mutations have rarely been reported in small cell lung carcinoma (SCLC). (nih.gov)
  • In addition to the clinicopathological characteristics of this rare histological type of lung cancer, these findings provide useful information for better understanding the biology, natural history and clinical management of SCLC. (nih.gov)
  • Solitary small bowel metastasis secondary to lung cancer is very uncommon. (hindawi.com)
  • The JTO is a prized resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer. (scienceblog.com)
  • The JTO is the official monthly journal of the International Association for the Study of Lung Cancer (IASLC.org) and emphasizes a multidisciplinary approach, including original research (clinical trials and translational or basic research), reviews and opinion pieces. (scienceblog.com)
  • Lung cancer is the most common cause of the malignant pleural effusions(MPE).For patients with lung cancer and MPE, the median survival is only 3-4 months.The aim of this study was evaluate the lung cancer patients with MPE clinical and laboratory findings on admission,analysis of 2 years survival and prognostic factors. (ersjournals.com)
  • This is a Phase 1b/2, multiple-dose study designed to describe safety and efficacy, and to assess PK and immunogenicity of XmAb18087 monotherapy and in combination with pembrolizumab in subjects with metastatic Merkel cell (MCC) or locoregional MCC that has recurred after locoregional therapy with surgery and/or radiation therapy, and XmAb18087 monotherapy in subjects with extensive-stage small cell lung cancer (SCLC) that has progressed after standard therapies. (centerwatch.com)
  • What do I need to know about caring for someone with non-small cell cancer? (sharecare.com)
  • Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas? (nih.gov)
  • To compare the presenting and prognostic characteristics of patients with large cell neuroendocrine lung cancer (LCNELC) with those of patients with small cell lung cancer (SCLC) or other large cell carcinomas (OLCs) and to compare overall survival (OS) and lung cancer-specific survival (LCSS) rates for patients undergoing definitive resection without radiotherapy (S-NoRT). (nih.gov)
  • Small cell lung cancer, another neuroendocrine tumor, is associated with paraneoplastic syndromes (PNS) in up to 20% of cases, notably the syndrome of inappropriate antidiuretic hormone (SIADH) and Lambert-Eaton myasthenic syndrome. (aad.org)
  • Aside from non-melanoma skin cancer, the most common malignancies in the US are breast cancer followed by lung cancer. (aad.org)
  • anti-epiligrin cicatricial pemphigoid, amongst others may be paraneoplastic disorders that may be secondary to lung cancer. (aad.org)
  • 3. Owen CO. Cutaneous manifestations of lung cancer. (aad.org)
  • It is more commonly associated with non-small-cell lung cancer, but the temporal association with Bowen's disease in the absence of other chemical or occupational exposure strongly points to a causal role for arsenic in this case of small-cell lung cancer. (thefreelibrary.com)
  • A diagnosis of extensive stage small-cell lung cancer was made. (thefreelibrary.com)
  • Listen as Dr. London Smith (.com) and his producer Cameron discuss Small Cell Lung Cancer with special guest Dr. Benjamin Evans. (stitcher.com)
  • It has recently been shown that nanoparticle albumin-bound paclitaxel (nab-PAC)+carboplatin (CBDCA) provides a favorable overall response rate in non-small cell lung cancer. (go.jp)
  • This is the first case report of nab-PAC+CBDCA therapy in small cell lung cancer (SCLC). (go.jp)
  • Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway. (selleckchem.com)
  • This case indicates that metastasis induced acute pancreatitis can be a manifestation of lung cancer, especially in small cell carcinoma. (eurekamag.com)
  • The frequencies of micronuclei were measured in lymphocytes of 6 patients with small cell lung cancer treated with a combination of cisplatin and etoposide and 7 patients with ovarian carcinoma treated with a combination of taxol and cisplatin. (ovid.com)
  • 3 patients with lung cancer received radiotherapy in addition to chemotherapy. (ovid.com)
  • Paraneoplastic syndrome (PNS) related to lung cancer is very common. (ecancer.org)
  • Utility of PET-CT in non-small cell lung cancer clinical stage IB-IIA according to AJCC 8th edition staging system: an alternative to invasive mediastinal staging? (ecancer.org)
  • Expression of the protein could have implications for progression of the disease because it regulates cancer cell growth, apoptosis, and angiogenesis. (aacrjournals.org)
  • Sex-dependent effects of PTHrP in lung cancer would open new avenues of research into the role of sex in cancer progression. (aacrjournals.org)
  • It is less widely appreciated that PTHrP also exerts effects direct effects on cancer cells that could be important in the pathology of malignancy. (aacrjournals.org)
  • Direct actions of PTHrP on cancer cells are frequently related to cell growth or life cycle. (aacrjournals.org)
  • For example, the protein alters the rate of proliferation in many cancer cell types ( 1 - 4 ) and can have regulatory effects on the propensity to undergo apoptosis ( 5 - 7 ). (aacrjournals.org)
  • PTHrP also modulates integrin ( 8 - 11 ) and metalloproteinase expression ( 12 ) in various cancer cells and inhibits angiogenesis ( 13 ). (aacrjournals.org)
  • A large body of work has evaluated the role of PTHrP in lung cancer-induced hypercalcemia ( 21 ), but few investigations have probed its role in lung cancer progression or survival. (aacrjournals.org)
  • An animal study from our laboratory suggested that PTHrP expression could hinder lung cancer growth ( 1 ). (aacrjournals.org)
  • Survival of patients with stage II non-small lung cancer by the 1986 classification depends on the type of lymph node involvement (by direct extension or by metastases in lobar or hilar lymph nodes). (ovid.com)
  • Lung cancer is the leading cause of cancer-related death throughout the world ( 1 ). (spandidos-publications.com)
  • Since the lack of symptoms and little help from traditional X-rays on early stage lung cancer, most patients are diagnosed with advanced stage disease and thus have poor prognosis. (spandidos-publications.com)
  • Some studies showed that human testicular orphan nuclear receptor-4 (TR4) repressed the ERβ-mediated transactivation of its downstream signal pathways in lung cancer cells and indicated that TR4 might be a potential tumor suppressor gene ( 17 ). (spandidos-publications.com)
  • Lung Cancer, 74(1):118-123. (uzh.ch)
  • IRAK-1 is a novel inflammation-related marker and a potential target for lung cancer chemopreventive strategies. (pubmedcentralcanada.ca)
  • Lung cancer is the leading cause of cancer-related deaths in the United States ( 1 ). (pubmedcentralcanada.ca)
  • The identification of novel molecular mechanisms involved in the pathogenesis and progression of premalignant lesions may provide with new strategies for risk assessment and early detection, chemoprevention, and treatment of lung cancer. (pubmedcentralcanada.ca)
  • In addition, inflammation and related pathways have been implicated in the pathogenesis of lung cancer, particularly in the tobacco related damage of the respiratory epithelium ( 3 , 7 , 8 ). (pubmedcentralcanada.ca)
  • Background: The ultimate goal of the study was to find a role of curcumin in targeting lung cancer stem cells by reducing their self-renewal efficiency causing DNA damage. (eurekaselect.com)
  • Materials and Methods: Circulating lung cancer stem cells were isolated by sphere formation assay and further analysed by flow-cytometry and qRT-PCR for the presence of stem cell and stem cell transcription markers. (eurekaselect.com)
  • Results and Conclusion: Our results demonstrated that curcumin significantly affect the self-renewal ability of circulating lung cancer stem cells. (eurekaselect.com)
  • Thus, we can conclude that curcumin can be used to target lung cancer stem cells which is responsible for the disease progression and metastasis by causing DNA damage or inhibiting their DNA repair mechanisms. (eurekaselect.com)
  • Sheefa Mirza, Aakanksha Vasaiya, Hemangini Vora, Nayan Jain and Rakesh Rawal*, "Curcumin Targets Circulating Cancer Stem Cells by Inhibiting Self-Renewal Efficacy in Non-Small Cell Lung Carcinoma", Anti-Cancer Agents in Medicinal Chemistry (2017) 17: 859. (eurekaselect.com)
  • In Vietnam, lung cancer has one of the highest death rates, with non-small-cell lung carcinoma accounting for 85% of patients being treated. (fvhospital.com)
  • These studies thus reveal a central role for ID1 and its downstream targets in facilitating lung cancer progression. (springer.com)
  • Sattler and Salgia, 2007 ) so that a detailed understanding of processes underlying c-Met-dependent cancer cell migration is important for providing opportunities for the development of new treatments for these diseases. (biologists.org)
  • We propose that TFP might be capable of inhibiting one or more elements of the DNA DSB repair machinery, thereby increasing the cytotoxicity of bleomycin in lung cancer cells. (diva-portal.org)
  • A group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. (semanticscholar.org)
  • Non-small cell lung carcinoma is a leading cause of cancer mortality worldwide. (diva-portal.org)
  • Wistuba, Ignacio 2018-06-06 00:00:00 Background: The clinical efficacy observed with inhibitors of programed cell death 1/programed cell death ligand 1 (PD-L1/PD-1) in cancer therapy has prompted studies to characterize the immune response in several tumor types, including lung cancer. (deepdyve.com)
  • Conclusions: NCT-NSCLCs exhibited higher levels of PD-L1 expression and T-cell subset regulationthannon-NCT-NSCLCs, suggesting that NCT activates specific immune response mechanisms in lung cancer. (deepdyve.com)
  • Although neoadjuvant chemotherapy (NCT) liferation, and inflammatory and immune cell activation for cancer has historically been considered immunosup- [1]. (deepdyve.com)
  • GAGE and NY-ESO-1 cancer/testis antigens were not expressed in normal lung tissue, while SP17 was expressed in ciliated lung epithelia. (biomedcentral.com)
  • In lung cancer, K- ras mutations occur predominantly in codon 12 ( 3 )( 4 )( 5 )( 6 )( 7 ). (aaccjnls.org)
  • The timing of K- ras activation in the process of lung cancer development is still unclear. (aaccjnls.org)
  • Several methods have been utilized for the detection of K- ras point mutations in lung cancer. (aaccjnls.org)
  • The pathological and molecular classification of lung cancer has become substantially more complex over the past decade. (ersjournals.com)
  • I read that lung cancer is one of the most common cancers, but what can you do to reduce the risk? (images.md)
  • Adenocarcinoma is the most common type of non-small-cell lung cancer accounting for around 40% of all cases. (images.md)
  • It is commonly found in current or former smokers but paradoxically, it is also the most common type of lung cancer found in people who have never smoked. (images.md)
  • Squamous cell lung carcinoma (also called epidermoid carcinoma) is a cancer that forms in the squamous cells, which are round, flat cells that replace injured or damaged cells in the lining of the lung's bronchi. (images.md)
  • These types of cancer account for around 9 % of all lung carcinomas and tend to be very fast growing. (images.md)
  • Other less common types of non-small cell lung cancer are: pleomorphic, carcinoid tumor, salivary gland carcinoma, and all carcinomas that are histologically unidentifiable known as unclassified lung carcinomas. (images.md)
  • 4. American Cancer Society: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer. (images.md)
  • Necrosis is associated with pathologic conditions while apoptosis is a physiological process of programmed cell death, which is associated with normal tissue growth and is frequently impaired in various forms of cancer. (springeropen.com)
  • Tumor necrosis and apoptotic index (AI) have been previously evaluated as prognostic biomarkers in lung cancer, but their exact clinical value remains unclear. (springeropen.com)
  • The prognosis of lung cancer remains poor. (springeropen.com)
  • This is the allocated stage for small-cell lung cancer if the tumours have spread beyond the hemi-thorax, the mediastinum or the supraclavicular lymph nodes of the affected side. (images.md)
  • Of the total number of cases of small-cell lung cancer it is estimated that around two out of three patients already have extensive disease at the time of diagnosis. (images.md)
  • This is due in part to the fact that small-cell lung cancer is an aggressive disease and the tumour or tumours grow and metastasise rapidly, so often by the time that symptoms have manifested the cancer has already spread. (images.md)
  • The most common sites of metastatic spread in lung cancer include the other lung, the adrenal gland or glands, bone, brain and liver. (images.md)
  • Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. (images.md)
  • In 2015, the World Health Organization (WHO) and the International Association for the Study of Lung Cancer (IASLC) updated their guidelines for the subclassification of lung cancers. (nih.gov)
  • Large cell carcinoma of the lung with a rhabdoid phenotype is a rare type of lung cancer, and does not commonly metastasize to the small intestine. (ersjournals.com)
  • Herein we describe a 63-yr-old Japanese male with ileus resulting from small intestinal metastasis from lung cancer. (ersjournals.com)
  • Pulmonary carcinoma is the most frequently diagnosed major cancer, although only a few cases of large cell carcinoma of the lung with rhabdoid phenotype (LCCRP) have been reported [ 1 ]. (ersjournals.com)
  • Metastases to the brain, bone, adrenal glands and liver are more common in patients with lung cancer, whereas small intestinal metastasis is rare [ 2 ]. (ersjournals.com)
  • The differential diagnosis between pleural malignant mesothelioma (MM) and lung cancer is often challenging. (nih.gov)
  • All 45 non-small cell lung cancer biopsies stained positive for nuclear BAP1, whereas 22/35 (63%) MM biopsies lacked nuclear BAP1 staining, consistent with previous data. (nih.gov)
  • To determine cytotoxic effects of single and blended mushroom extracts, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and neutral red assays were conducted using human small cell lung cancer, lung adenocarcinoma, colon cancer, and brain astrocytoma cancer cells. (begellhouse.com)
  • During recent years, the crosstalk between the cancer cells and the tumor stroma, highly responsible for the progression of tumors and their metastasis, has been increasingly unveiled. (upv.es)
  • This review reports novel data on the essential crosstalk between cancer cells and cells of the tumor stroma, with an emphasis on the role played by CAFs. (upv.es)
  • Furthermore, it presents recent literature on relevant tumor stroma- and CAF-related research in non-small cell lung cancer. (upv.es)
  • Lungs - Cancer - Molecular aspects. (hku.hk)
  • We have found that the oncogene c-myb is differentially expressed in human lung cancer cell lines and that myb-homolo-gous RNA can be detected only in small cell lung cancer (SCLC) cell lines. (elsevier.com)
  • A 3.5-kilobase RNA transcript homologous to v-myb is present in four of four lines of classic SCLC and in three of four SCLC variant lines but not in five of five non-small cell lung cancer lines tested. (elsevier.com)
  • Griffin, CA & Baylin, SB 1985, ' Expression of the c-myb Oncogene in Human Small Cell Lung Carcinoma ', Cancer Research , vol. 45, no. 1, pp. 272-275. (elsevier.com)
  • Small cell lung cancer (SCLC) or Small Cell Carcinoma (Lung), formerly known as oat cell carcinoma, accounts for 10-15% of all lung cancers. (withoutaribbon.org)
  • However, there is a strong link between the presence or diagnosis of small cell lung cancer and chronic tobacco smoking. (withoutaribbon.org)
  • Other risk factors for developing small cell lung cancer are the working history in uranium mines and long-term exposure to radon gas. (withoutaribbon.org)
  • Worldwide, lung cancer is the most common malignant neoplasm in men and the fifth most common cancer in women. (withoutaribbon.org)
  • In Europe, lung cancer is the 2nd common cancer after prostate cancer. (withoutaribbon.org)
  • Small Cell Carcinoma (Lung) is a rare cancer, meaning it is not as well known as other forms of cancer. (withoutaribbon.org)
  • If you suffer from rare cancer such as Small Cell Carcinoma (Lung), we can help and support you through your journey thanks to the generous donations we receive. (withoutaribbon.org)
  • EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. (rush.edu)
  • A Little Bit of Cancer is Still Cancer: Is it Time for Lymph Node Micrometastases in Non-small Cell Lung Cancer to Get Their Due? (rush.edu)
  • The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. (rush.edu)
  • Here's Boston's Dana-Farber Cancer Center's quick-and-dirty cartoon video about how the anti-PD-1 drug hooks up with the PD-L1 expression on the cancer cell (antigen). (biomednews.org)
  • Months after she'd received the treatment for early-stage adenocarcinoma, a type of non-small cell lung cancer, the woman came back suffering. (biomednews.org)
  • Presentation] IASLC 2019 World Conference on Lung Cancer. (pharmaceutical-journal.com)
  • In these cases, the tumors are classified as combined small cell lung carcinoma (c-SCLC), [7] and are (usually) treated like "pure" SCLC. (wikipedia.org)
  • LCLC is differentiated from small cell lung carcinoma (SCLC) primarily by the larger size of the anaplastic cells, a higher cytoplasmic-to-nuclear size ratio, and a lack of "salt-and-pepper" chromatin. (wikipedia.org)
  • Small cell carcinoma of the lung (SCLC) together with the large cell neuroendocrine carcinoma (LCNEC), typical carcinoid (TC), and atypical carcinoid (AC) make a group of morphologically identifiable neuroendocrine tumors. (srce.hr)
  • The differential diagnosis of SCLC includes, first of all, other neuroendocrine tumors, and primary or metastatic non-small cell carcinomas. (srce.hr)
  • As a result, it is recommended that all multiphasic malignant lung tumors (i.e. those with more than one histological pattern) that are found to contain any proportion of SCLC cells should be classified as c-SCLC, and not as combined forms of any of the other histological variants present in the tumor. (wikipedia.org)
  • In these instances, a minimum of 10% of the viable malignant cells present must be identified as LCLC before the tumor is considered to be a c-SCLC. (wikipedia.org)
  • Daughter cells of this transdifferentiated SCLC-like cell then repeatedly divide and, under both intrinsic genomic and extrinsic environmental influences, acquire additional mutations (a process known as tumor progression). (wikipedia.org)
  • Other molecular studies, however, suggest that - in at least a minority of cases - independent development of the components in c-SCLC occurs via mutation and transformation in two different cells in close spatial proximity to each other, due to field cancerization. (wikipedia.org)
  • Regardless of which of these mechanisms give rise to the tumor, recent studies suggest that, in the later stages of c-SCLC oncogenesis, continued mutational progression within each tumor component results in the cells of the combined tumor developing molecular profiles that more closely resemble each other than they do cells of the "pure" forms of the individual morphological variants. (wikipedia.org)
  • Our patient was a 72-year-old man with stage IV SCLC combined with squamous cell carcinoma and interstitial lung disease (ILD). (go.jp)
  • Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. (aacrjournals.org)
  • Consistent with these findings, murine non-neuroendocrine SCLC tumors are rejected in a syngeneic model, with clonal expansion of immunodominant effector CD8 T cells. (aacrjournals.org)
  • Therapeutically, EZH2 inhibition followed by STING agonism enhances T cell recognition and rejection of SCLC in mice. (aacrjournals.org)
  • No novel chemotherapeutic combinations have demonstrated superior efficacy to etoposide/cisplatin (EP), a standard treatment regimen for extensive-stage small cell lung carcinoma (ES-SCLC) over the past decade. (biomedcentral.com)
  • In 2015, large cell neuroendocrine carcinoma (LCNEC) was removed from the large cell carcinoma group and classified with small cell lung carcinoma (SCLC) constituting two members of the high-grade neuroendocrine tumors (NETs) of the lung. (jcancer.org)
  • These results suggested that high-grade LCNEC and high-grade SCLC were different histological types, and that a detailed classification for high-grade NETs of the lung was needed. (jcancer.org)
  • Small cell lung carcinoma (SCLC) is a tumour of neuroendocrine origin often found in association with autoimmune paraneoplastic neurological disorders. (ox.ac.uk)
  • We established a SCLC cell line from a woman with Lambert-Eaton myasthenic syndrome (LEMS) who developed antibodies to both the P/Q-type voltage-gated calcium channels (VGCC) and the muscle acetycholine receptor (AChR). (ox.ac.uk)
  • The results show that many proteins involved in exocytosis are present in the SCLC cells, and that depolarisation-dependent release of [(3)H]-serotonin is linked to calcium influx through P/Q-type VGCCs. (ox.ac.uk)
  • The distinction between small cell lung carcinoma (SCLC) and small cell carcinomas of other sites is difficult by routine histology. (avmi.net)
  • TTF-1 expression has also been demonstrated in adenocarcinomas of the thyroid and lung, and SCLC. (avmi.net)
  • However, the value of TTF-1 immunostaining in discriminating between SCLC and nonpulmonary small cell carcinomas has not been investigated. (avmi.net)
  • Sixteen (89%) of the 18 Merkel cell carcinomas and one SCLC were CK20-positive. (avmi.net)
  • These results indicate that although TTF-1 is not a specific marker for SCLC, it may assist in distinguishing SCLC from some nonpulmonary small cell carcinomas, particularly Merkel cell carcinoma, especially when it is used in conjunction with CK20. (avmi.net)
  • Surgery is the main option, all patients with stages I SCLC lung should undergo surgical resection of the tumour (complete removal of the tumour along with the removal of some surrounding healthy tissues). (withoutaribbon.org)
  • Pneumonectomy (surgical removal of the entire lung), lobectomy (removal of a lobe of a lung) should also be considered in the earlier stages of SCLC when the tumour has spread to most of the lung or lobe of the lung. (withoutaribbon.org)
  • Although the criteria for the morphologic separation from other tumors of the lung are defined, in everyday practice it can be a problem, both in cytology and with histological samples. (srce.hr)
  • Two additional RB positive primary tumors have major foci in which all tumor cells showed no RB protein staining. (aacrjournals.org)
  • B, the combination enhanced the suppression of cell proliferation in the tumors derived from the hHGF tg -SCID mice. (aacrjournals.org)
  • Keywords: Tumor compartments, Epithelial compartment, Stromal compartment, Adenocarcinoma, Squamous cell carcinoma, Survival, T cells Background suggesting that strategies to control and modify the im- Tumors grow by using a complex composite system that mune cell population are important approaches to can- includes epithelial and stromal cell activation, vessel pro- cer therapy. (deepdyve.com)
  • Wang J, Ye L, Cai H, Jin M. Comparative study of large cell neuroendocrine carcinoma and small cell lung carcinoma in high-grade neuroendocrine tumors of the lung: a large population-based study. (jcancer.org)
  • Among the nonpulmonary small cell carcinomas, two tumors of the gastrointestinal tract, one of the bladder, and one of the uterine cervix exhibited TTF-1 positivity. (avmi.net)
  • Immunohistochemical analysis of tumor sections showed moderate-to-high grade signals for EGFR and adenovirus, and a reduction in viable cells in Ad/SA-treated tumors. (elsevier.com)
  • Pie chart showing incidences of non-small cell lung cancers as compared to small cell carcinoma shown at right, with fractions of smokers versus non-smokers shown for each type. (wikipedia.org)
  • [9] Adenocarcinomas account for approximately 40% of lung cancers. (wikipedia.org)
  • Large-cell carcinoma accounts for 10-15% of lung cancers, typically manifesting as a large peripheral mass on chest radiograph. (medscape.com)
  • [ 11 ] Large-cell undifferentiated cancers carry the same prognosis as do adenocarcinomas and are combined with them in clinical trials. (medscape.com)
  • Soy consumption reduces the risk of non-small-cell lung cancers with epidermal growth factor receptor mutations among Japanese. (greenmedinfo.com)
  • Approximately 99% of lung cancers are carcinoma, a term that indicates that the malignant neoplasm is composed of, or descended from, cells of epithelial lineage (i.e. derived from embryonic endoderm, as is the case in lung carcinomas, or from ectoderm), and/or that the malignant cells exhibit tissue architectural, cytological, or molecular features characteristically found in epithelial cells. (wikipedia.org)
  • The exact mechanisms and histogenesis of lung cancers are topics of intense interest and research. (wikipedia.org)
  • Approximately 98% of lung cancers are eventually diagnosed as a histological variant of carcinoma, a term that signifies that the tumor derives from transformed epithelial cells, or cells that have acquired epithelial characteristics as a result of cell differentiation. (wikipedia.org)
  • The classification of lung cancers are divided into two main categories:- non-small-cell lung carcinoma (NSLC) and small-cell lung carcinoma (SCL) (3) this distinction is useful for therapeutic purposes as management and treatment tends to be similar for non-small-cell lung cancers and quite different for small-cell cancers. (images.md)
  • (4) The three main types of non-small-cell lung cancers, are classified according to the types of cells involved, and are adenocarcinoma (see Image 1), squamous cell carcinoma (see Image 2) and large-cell carcinoma (see image 3). (images.md)
  • Squamous-cell carcinoma is primarily caused by smoking (5) and accounts for around 30% of all lung cancers. (images.md)
  • According to studies around 90 - 95% of small-cell lung cancers are centrally located and usually arise in a main bronchus or a lobar bronchi (a subdivision of the bronchus) and appear as hilar or perihilar growths. (images.md)
  • The remaining 5 - 10% of small-cell lung cancers present in a peripheral position of the lung. (images.md)
  • (3) Small-cell lung cancers tend to be aggressive, so even though the cells are small the tumours grow rapidly and are more widely metastatic (have a greater tendency to spread to other parts of the body) than non-small cell lung cancers. (images.md)
  • Used alone and sometimes in combination with other drugs or modalities, the drugs are forcing a certain percentage of melanomas and smoking-induced lung cancers to yield. (biomednews.org)
  • Large cell lung carcinoma (LCLC) is a heterogeneous group of undifferentiated malignant neoplasms originating from transformed epithelial cells in the lung. (wikipedia.org)
  • Research of Non-small Cell Lung Carcinoma has been linked to Malignant Neoplasm Of Lung, Malignant Neoplasms, Lung Neoplasms, Neoplasms, Carcinoma. (novusbio.com)
  • Histologically, this type has sheets of highly atypical cells with focal necrosis, with no evidence of keratinization (as is typical of SCC) or gland formation (as is typical of adenocarcinomas). (medscape.com)
  • With improved histopathologic procedures and the use of electron microscopy, most NSCLCs that would previously have been classified as large-cell carcinomas are identified as undifferentiated adenocarcinomas or, less frequently, as SCCs. (medscape.com)
  • Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. (medscape.com)
  • Squamous cell carcinomas (SCC) are more frequent among smoking men while females develop adenocarcinomas (ADCA). (diva-portal.org)
  • MATERIAL AND METHODS: Material from 29 cases of lung carcinoma (small cell, squamous cell, and adenocarcinomas) was examined immunohistochemically for Ki-67 and p53 expression in virtually constructed cylinders of different diameters. (diva-portal.org)
  • When Point-EXACCT was used, K- ras codon 12 mutations were detected in 8 of 52 patients with squamous cell carcinomas, 10 of 29 patients with adenocarcinomas, and 3 of 8 patients with large cell carcinomas. (aaccjnls.org)
  • K- ras point mutations are found in approximately 15-56% of the adenocarcinomas and to a lesser extent in other types of non-small cell lung carcinomas (NSCLCs) ( 3 )( 5 )( 7 )( 8 )( 9 )( 10 )( 11 )( 12 )( 13 )( 14 ). (aaccjnls.org)
  • Selected agents ( e.g. pemetrexed and nintedanib) show superior efficacy in adenocarcinomas and large cell carcinomas when compared to squamous cell carcinomas (SqCC) [ 2 - 5 ]. (ersjournals.com)
  • (2) Adenocarcinomas usually occur in the peripheral (or outer) portion of the lungs. (images.md)
  • Tumour is on the left, obstructing the bronchus (lung). (wikipedia.org)
  • In line with the isoform-specific requirement of ERK2 for HGF-mediated migration in lung tumour cell models, ERK2 but not ERK1 is shown to be responsible for paxillin serine 126 phosphorylation and its increased turnover at focal adhesions. (biologists.org)
  • The tumour contains dense core granules similar to the argentaffin cell granules of the gastrointestinal tract and actively secretes hormones and hormone like products. (gpnotebook.com)
  • oat cell tumour - characterised by uniform small - to - medium sized, closely packed cells arranged in strands, clusters, or singly, with dark-staining nuclei and a high nuclear:cytoplasmic ratio. (gpnotebook.com)
  • Liquid biopsies ( i.e. analysis of cell-free tumour DNA from blood plasma) have become another important option in such a situation, but are not within the scope of this review. (ersjournals.com)
  • If these lesions grow to a large size hollow cavities appear that are associated with cell death and commonly found at the centre of the tumour, as demonstrated in the above case. (images.md)
  • Large-cell carcinoma is a name that is given to any tumour that cannot be definitively histologically classified as a small-cell, squamous-cell or adenocarcinoma. (images.md)
  • We used a range of techniques to establish which neuronal antigens were expressed in her tumour cell line. (ox.ac.uk)
  • Frontal Chest X-Ray demonstrating a small visible tumour confined to the left upper lobe of the lung with no mediastinum (the membranous partition between the lungs) involvement and no signs of supraclavicular ipsilateral lymph nodes involved. (images.md)
  • There is a lower lung nodule noted on the right lung (purple circle) that is suggestive of a secondary tumour indicating metastatic spread to the opposite lung. (images.md)
  • Based on these clinical findings, we diagnosed the patient as having primary lung tumour with metastasis to the small bowel. (ersjournals.com)
  • Large tumour cells were mainly located in the submucosa and invaded the vessel (arrow) (haematoxylin and eosin stain. (ersjournals.com)
  • Pathological findings of the specimen showed several large tumour cells similar to those in the intestinal lesion shown in (a). (ersjournals.com)
  • c) Enlarged view of boxed section in (b) showing several large tumour cells (arrow). (ersjournals.com)
  • However, the lung tumour quickly enlarged and pleural effusion developed within 3 weeks. (ersjournals.com)
  • This is most often the case when a pathologist examines a small amount of malignant cells or tissue in a cytology or biopsy specimen. (wikipedia.org)
  • The invention also comprises a method for determining the presence of a malignant condition in lung tissue and other human tissue. (freepatentsonline.com)
  • Human normal bronchial and alveolar epithelial cells were also reported to express ERβ, which was considered to contribute to the maintenance of normal lung tissue ( 7 ). (spandidos-publications.com)
  • In general in tumor tissue, a variable number of nonmalignant cells, such as stromal and inflammatory cells, are mixed with tumor cells. (aaccjnls.org)
  • Small samples (biopsy and cytology) require "tissue" management, which is best achieved by the interaction of all physicians involved. (ersjournals.com)
  • Resulting necrosis is characterized by the presence of dead cells in the form of anucleate "ghost cells', but with preservation of the tissue architecture (Kumar et al. (springeropen.com)
  • On pathological examination of the resected small bowel tissue ( fig. 2a ) and the lung biopsy specimen ( fig. 2b and c), the microscopic appearances of these specimens were identical. (ersjournals.com)
  • EN] Maintenance of both normal epithelial tissues and their malignant counterparts is supported by the host tissue stroma. (upv.es)
  • In 76% of cases (38/50) cytological diagnosis of small cell lung carcinoma was also confirmed histologically. (srce.hr)
  • In 8% of cases (4/50) adenocarcinoma was histologically confirmed, in 10% (5/50) of the cases the squamous carcinoma was confirmed, and there was one case of urothelial carcinoma, one case of sarcoma and one undifferentiated carcinoma. (srce.hr)
  • These lesions were characterised histologically by the presence of typical rhabdoid cells, which are large cells with abundant cytoplasm and eccentric nuclei with central macronucleoli. (ersjournals.com)
  • [10] [11] However, recent studies suggest that the "ratio of centrally-to-peripherally occurring" lesions may be converging toward unity for both adenocarcinoma and squamous cell carcinoma. (wikipedia.org)
  • The patient was diagnosed with Bowen's disease and developed extensive-stage small-cell carcinoma of the lung 10 years and 47 years, respectively, after the onset of arsenic exposure. (thefreelibrary.com)
  • However, acute pancreatitis caused by metastatic carcinoma of the pancreas is an uncommon condition with a poor prognosis. (eurekamag.com)
  • Association of HAb18G with clinicopathologic features and prognosis in non-small cell carcinoma of lung]. (semanticscholar.org)
  • bcl-2 and prognosis in non-small-cell lung carcinoma. (ox.ac.uk)
  • In the remaining 77 patients, histological verification of cytological diagnosis was not made and the patients were treated based on cytological diagnosis of small cell carcinoma. (srce.hr)
  • Currently, the only exception to this recommendation occurs in cases where anaplastic large cell lung carcinoma (LCLC) is the second histological component. (wikipedia.org)
  • These pathways complement our catalog of research reagents for the study of Non-small Cell Lung Carcinoma including antibodies and ELISA kits against EGFR, TP53, VEGFA, MID1, CDKN2A. (novusbio.com)
  • No somatic mutations were detected in the mutation cluster regions of the KRAS, EGFR, BRAF and PIK3CA genes and the entire coding region of p53 in the carcinoma, and the expression of ALK fusion was negative. (spandidos-publications.com)
  • The lysates from indicated cell lines were subjected to immunoprecipitation with anti-EGFR antibody, followed by Western blot analysis for MET in the immune complexes. (aacrjournals.org)
  • C and D, inhibition by SGX523 and/or erlotinib of ligand-dependent and -independent activation of MET, EGFR, and their downstream signaling in MET-amplified cells. (aacrjournals.org)
  • Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. (selleckchem.com)
  • On August 31st2019, Ho Chi Minh City Oncology Hospital cooperated with AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, to hold a Scientific Seminar About Diagnosing and Treating Non-Small-Cell Lung Carcinoma Having EGFR Mutation for doctors to discuss and share their experiences in treating the condition. (fvhospital.com)
  • Promoter activity of S100A2 was greatly restricted to tumor cells, and the S100A2 promoter bound with typical nuclear targets of epidermal growth factor receptor (EGFR) signaling. (elsevier.com)
  • Bronchoscopy revealed a right middle-lobe tumor, and the biopsy was positive for small-cell lung carcinoma. (thefreelibrary.com)
  • In 1993, a skin biopsy of a lesion on his right elbow was positive for squamous cell carcinoma in situ. (thefreelibrary.com)
  • We performed percutaneous needle biopsy of the lung lesion for diagnosis. (ersjournals.com)
  • b) Lung specimen obtained by percutaneous needle biopsy. (ersjournals.com)
  • To the best of our knowledge, this is the first case report describing a prolonged survival in a patient with a symptomatic solitary small bowel metastasis treated with palliative surgery, chemo- and radiotherapy instead of complete surgical resection. (hindawi.com)
  • It has been hypothesized that chronic inflammation is a major consequence of certain environmental factors eventually leading to increased proliferation, survival, and migration of epithelial cells, as well as angiogenesis in the adjacent stroma, thereby promoting epithelial tumor development ( 4 - 6 ). (pubmedcentralcanada.ca)
  • In the present study, we investigated the effect of trifluoperazine on (a) survival of bleomycin-treated human non-small cell lung carcinoma U1810 cells, (b) induction and repair of bleomycin-induced DNA strand breaks, and (c) nonhomologous end-joining (NHEJ), the major DNA double-strand break (DSB) repair pathway in mammalian cells. (diva-portal.org)
  • Taking nivolumab for advanced non-small cell lung carcinoma is associated with a better five-year survival rate than taking docetaxel. (pharmaceutical-journal.com)
  • Ursolic Acid and oleanolic acid reduced the proliferation of A549 cells in nude mice. (greenmedinfo.com)
  • In a small interfering RNA (siRNA)-based high-throughput wound healing screen performed in A549 lung carcinoma cells, we identified ERK2 but not ERK1 as a strong mediator of HGF-induced motility. (biologists.org)
  • Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. (nih.gov)
  • Merkel cell polyomavirus infection and Merkel cell carcinoma. (aad.org)
  • Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. (aad.org)
  • Densities of CD3+ cells in the tumor epithelial compartment were higher in NCT-ADCs and NCT-SCCs than in non-NCT-ADCs and non-NCT-SCCs (P = 0.043). (deepdyve.com)
  • 0.001) cells in the tumor epithelial compartment. (deepdyve.com)
  • Large-cell lung carcinoma refers to a diverse group of malignant tumours that originate from the epithelial cells of the lung. (images.md)
  • Thyroid transcription factor-1 (TTF-1) is a homeodomain-containing transcription factor that is selectively expressed in thyroid and pulmonary epithelial cells. (avmi.net)
  • This is a randomized phase II study designed to evaluate the effect of local consolidative radiation therapy (LCT) to all sites of oligoprogressive disease in patients with metastatic non-small cell lung carcinoma who have progressed through first line systemic therapy containing an immune checkpoint inhibitor (ICI). (clinicaltrials.gov)
  • It accounts for about 20 - 30% of lung tumours. (gpnotebook.com)
  • Squamous cell tumours usually occur in the central portion of the lung or in one of the main airway branches. (images.md)
  • Approximately 30% of small-cell lung tumours are found at this stage as seen in Image 1. (images.md)
  • In these tumours neoplastic cells fill up the alveoli and the only vessels present appear to belong to the trapped alveolar septa. (ox.ac.uk)
  • In the present study we have characterised the phenotype of the vessels present in these non-angiogenic tumours, in normal lung and in angiogenic non-small cell lung carcinomas. (ox.ac.uk)
  • A monoclonal antibody (mAb L6) to a small-cell lung carcinoma surface antigen recognizes a common epitope of vasopressin-neurophysin and oxytocin-neurophysin in hypothalamic nuclei. (pnas.org)
  • Transient EZH2 inhibition expands these non-neuroendocrine cells, which display intrinsic innate immune signaling and basally restored antigen presentation. (aacrjournals.org)
  • Chemotherapy has a potential to trigger nant cells have developed sophisticated mechanisms and immune activation by inducing immunogenic cell death pathways through which they regulate negative and posi- and subsequent tumor-associated neoantigen release, tive signals, blocking cytotoxic T cell activation and which in turn activates antigen-presenting cells (APCs) regulatory T cells and thus promoting tumor growth and such as tumor-associated macrophages (TAMs) and eventual tumor metastasis [2]. (deepdyve.com)
  • A few of the less common types are pleomorphic, carcinoid tumor, salivary gland carcinoma, and unclassified carcinoma. (wikipedia.org)
  • We now report on the identification of a neurophysin-like precursor in human lung carcinoma (LX-1) cell membrane. (pnas.org)
  • Cytologic specimens for diagnosis or for cell type classification must have been obtained from bronchial brushings or washings or from needle aspiration of a defined lesion. (pfizer.com)
  • Tumor necrosis and the apoptotic index (i.e. the proportion of apoptotic cells in tumor specimens) are two such features. (springeropen.com)
  • This cell line was established from a lung metastasis from a person with lung small cell carcinoma. (mskcc.org)
  • High level of serum CRP,lower serum albumin,lower pleural protein,MPE with distant metastasis were determined to be the most important prognostic factors for non small cell lung carcinoma patients with MPE. (ersjournals.com)
  • Concomitant therapy with other anti-neoplastic agents or experimental agents except for small volume radiation to a solitary bony metastasis. (knowcancer.com)
  • To our knowledge, there are no previous case reports describing intussusception of the small intestine caused by small intestinal metastasis of LCCRP. (ersjournals.com)
  • Although most host cells in the stroma possess certain tumor-suppressing abilities, the stroma will change during malignancy and eventually promote growth, invasion, and metastasis. (upv.es)
  • [1] [2] As a class, NSCLCs are relatively insensitive to chemotherapy , compared to small cell carcinoma. (wikipedia.org)
  • Thirteen months earlier, he developed small cell carcinoma of the lung and received 6 cycles of chemotherapy. (eurekamag.com)
  • Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. (harvard.edu)
  • Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung. (deepdyve.com)
  • In normal situations, T lymphocytes recognize ma- pressive, it is now accepted that certain chemotherapy lignant cells as abnormal and activate cytotoxic T lym- agents, such as paclitaxel, cisplatin, gemcitabine, and phocytes through helper T cells at the site, which carboplatin, can regulate and modulate antitumor im- infiltrate and kill the malignant cells. (deepdyve.com)
  • Can bronchoalveolar carcinoma be prevented? (sharecare.com)
  • Because little is known about the actual cause of bronchoalveolar carcinoma, little is known about how to prevent it. (sharecare.com)
  • How do I manage bronchoalveolar carcinoma on a daily basis? (sharecare.com)
  • If you have been diagnosed with bronchoalveolar carcinoma, it is important to begin treatment immediately to prevent the malignant tumor from metastasizing (spreading). (sharecare.com)
  • Because bronchoalveolar carcinoma cells are known to be spread out throughout the lungs, it is crucial that you find and remove cancerous cells as soon as possible. (sharecare.com)
  • Ask your doctor how to stay healthy while being treated for bronchoalveolar carcinoma. (sharecare.com)
  • Frontal Chest X-Ray indicating bronchial Carcinoma. (images.md)
  • Findings: Adenocarcinoma: Bronchial carcinoma with lymphadenopathy. (images.md)
  • Small-cell carcinomas are thought to originate from neuroendocrine cells that can be found in the bronchial mucosa. (images.md)
  • An abdominal CT showed a well-defined lesion in the superior right hepatic lobe consistent with a hepatic cyst and a mildly enlarged and heterogeneous left hepatic lobe concerning for possible hepatocellular carcinoma. (hindawi.com)
  • Pulmonary large cell neuroendocrine carcinoma: a true high-grade neuroendocrine tumor needing prospective therapeutic data. (nih.gov)
  • Expression rate also associated more so with adenocarcinoma histology (39 percent) than in squamous cell carcinoma histology (23 percent). (scienceblog.com)
  • Therefore, the use of relatively insensitive methods for point mutation detection, which can not discriminate cells containing a mutation in a background of cells with wild-type DNA, could lead to underestimation of positive cases. (aaccjnls.org)
  • These findings suggest expression of a pro-pressophysin-like protein in this tumor cell line that is preferentially targeted to the cell membrane. (pnas.org)
  • DLC-1's ability to induce tumor cell apoptosis is supported by the induction of caspase 3 activation in DLC-1-transfected cells following the morphological changes. (cdc.gov)
  • The minimal tumor cell fraction necessary for most methods is not well established. (aaccjnls.org)
  • In addition, the comparison of investigated blended mushroom extracts with three well-known commercial mushroom products derived from single mushroom species or single mushroom compounds shows that blended mushroom extracts exhibit significantly stronger cytotoxic effects on human tumor cell lines. (begellhouse.com)
  • In an attempt to define the role of initial surgical resection in patients with undifferentiated small cell carcinoma of the lung, we reviewed the experience of the Veterans Administration Surgical Oncology Group (VASOG). (nih.gov)
  • Researched pathways related to Non-small Cell Lung Carcinoma include Angiogenesis, Cell Cycle, Cell Proliferation, Cell Growth, Methylation. (novusbio.com)
  • The recent discovery of fusion oncokinases in a subset of non-small cell lung carcinomas (NSCLCs) is of considerable clinical interest, since NSCLCs that express such fusion oncokinases are reportedly sensitive to kinase inhibitors. (spandidos-publications.com)
  • In clinical practice and research trials small-cell carcinoma is divided into two main classifications which are:- limited and extensive disease. (images.md)
  • Therefore, LCNELC should continue to be classified and treated as a large cell carcinoma. (nih.gov)
  • Identity, similarity, and difference between large cell neuroendocrine carcinoma and small cell carcinoma. (nih.gov)
  • Large-cell carcinomas are so named because the cells appear large and rounded under a microscope with excess cytoplasm cytoplasm (all the material in a living cell except the nuclei) and large nuclei. (images.md)
  • Findings: Small-Cell Lung Carcinoma Limited Stage Disease. (images.md)
  • DOI=10.1073/pnas.81.2.568 Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O. Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies. (mskcc.org)
  • On average, the frequencies of micronuclei increased during the first half of therapy and declined thereafter, reaching, in some patients with ovarian carcinoma, values below the pre-treatment level. (ovid.com)
  • Green Tea induces apoptosis in drug-resistant small-cell lung carcinoma. (greenmedinfo.com)
  • DLC-1 tumor supressor gene induces apoptosis in human non-small cell lung carcinoma cells following a unique process of cell morphological changes and protein nuclear translocation. (cdc.gov)
  • New studies revealed that DLC-1 transfection can initially induce multiple branched cytoplasmic extensions, which are followed by membrane blebbing along the cytoplasmic extensions and progressive cell shrinkage, and ended with cytoplasmic and nuclear decomposition, the morphological evidence of cell apoptosis. (cdc.gov)
  • The process of morphological change is associated with RhoGAP-domain-related reduction of stress fibers and filopodia early in gene transfection and with collapsing of the actin cytoskeleton at the time of cell apoptosis. (cdc.gov)
  • However, the induction of cell apoptosis is more dependent on DLC-1 protein nuclear translocation, which could be retarded by active RhoA signaling. (cdc.gov)
  • Necrosis and apoptosis represent two pathogenetically distinct types of cell death. (springeropen.com)
  • There are two distinct types of cell death in terms of pathogenesis: necrosis and apoptosis. (springeropen.com)
  • Sputum cytology alone will not be acceptable for diagnosis or for cell type classification. (pfizer.com)
  • Miličić V, Prvulović I, Mišić M, Perić M, Samardžić S, Tomić K. Value of Cytology in Small Cell Lung Carcinoma Diagnostic - Single-Center Study. (srce.hr)
  • A case of Bowen's disease and small-cell lung carcinoma: long-term consequences of chronic arsenic exposure in Chinese traditional medicine. (thefreelibrary.com)
  • The study of Non-small Cell Lung Carcinoma has been mentioned in research publications which can be found using our bioinformatics tool below. (novusbio.com)
  • We have 3225 products for the study of Non-small Cell Lung Carcinoma that can be applied to Western Blot, Chromatin Immunoprecipitation, Immunocytochemistry/Immunofluorescence, Flow Cytometry, Chromatin Immunoprecipitation (ChIP), Immunohistochemistry from our catalog of antibodies and ELISA kits. (novusbio.com)
  • In view of this evidence for calcium-spike electrogenesis and previous evidence of secretory activity in these cells, this cell line (DMS 53) can provide a model for the study of excitation-secretion behavior in human neoplastic cells. (sciencemag.org)
  • Between 2008-2011, the retrospective cohort study was done in Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital and 199 cases of non small cell lung carcinoma with MPE were examined. (ersjournals.com)
  • The aim of this retrospective study was to characterize and quantify PD-L1/PD-1 expression and tumor-associated immune cells (TAICs) in surgically resected NSCLCs from patients who received NCT or did not receive NCT (non-NCT). (deepdyve.com)
  • Our study indicated that absence of nuclear BAP1 stain helps differentiate MM from lung carcinomas. (nih.gov)
  • We have previously described a group of non-small cell lung carcinomas without morphological evidence of neo-angiogenesis. (ox.ac.uk)
  • In addition there is a small left pleural effusion (pleural effusion is an execess of fluid that gathers in the pleural cavity). (images.md)
  • We have attempted to standardize our lung resection technique using 6 areas of dissection to gain in efficacy and save time. (websurg.com)
  • Affiliated tissues include lung . (malacards.org)
  • These results reveal that these extracts exhibit different cytotoxic effects on tumor cells originating from different tissues. (begellhouse.com)